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Research highlights: 
 Autophagy delivers cytoplasmic cargoes to lysosomes for degradation 
 It degrades many aggregate-prone proteins responsible for neurodegenerative 
disease 
 Enhancing autophagy has therapeutic potential in common neurodegenerative 
diseases 
 Evidence in cells and in vivo demonstrates promising results in many disease models 







Autophagy is a major, conserved cellular pathway by which cells deliver cytoplasmic contents 
to lysosomes for degradation. Genetic studies have revealed extensive links between 
autophagy and neurodegenerative disease, and disruptions to autophagy may contribute to 
pathology in some cases. Autophagy degrades many of the toxic, aggregate-prone proteins 
responsible for disease, including mutant huntingtin (mHTT), alpha-synuclein (α-syn), tau and 
others, raising the possibility that autophagy upregulation may help to reduce levels of toxic 
protein species and thereby alleviate disease. This review examines autophagy induction as 
a potential therapy in several neurodegenerative diseases – Alzheimer’s disease, Parkinson’s 
disease, polyglutamine diseases, and amyotrophic lateral sclerosis. Evidence in cells and in 
vivo demonstrates promising results in many disease models, in which autophagy 
upregulation is able to reduce the levels of toxic proteins, ameliorate signs of disease, and 
delay disease progression. However, effective therapeutic use of autophagy induction 
requires a detailed knowledge of how the disease affects the autophagy-lysosome pathway, 
as activating autophagy when the pathway cannot go to completion (e.g. when lysosomal 
degradation is impaired) may instead exacerbate disease in some cases. Investigating the 
interactions between autophagy and disease pathogenesis is thus a critical area for further 
research. 
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Macroautophagy (henceforth referred to as autophagy) is a major, conserved cellular process 
by which cells deliver cytoplasmic contents to lysosomes for degradation. This transport 
involves delivery of these contents by double-membraned vesicles called autophagosomes, 
in contrast with other pathways, like chaperone-mediated autophagy (CMA) and 
microautophagy, which do not involve vesicular transport. While autophagy was initially 
characterised as a primordial, non-selective degradation pathway induced to counteract 
nutrient deprivation, it has become increasingly clear that autophagy plays a key role in the 
homeostasis of non-starved cells. Critically, autophagy appears to degrade aggregate-prone 
proteins, damaged mitochondria, and invading pathogens, and these functions appear to be 
linked to a range of human diseases1, 2. 
One area of particular interest is the relevance of autophagy to neurodegenerative diseases. 
Many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and 
Huntington’s disease, arise from the accumulation of oligomers and aggregates of misfolded 
proteins. As these proteins exert toxic effects on cells, lowering the levels of these proteins 
can be therapeutically favourable1. Autophagy degrades many of the toxic aggregate-prone 
proteins responsible for disease, including mutant huntingtin (mHTT), alpha-synuclein (α-syn), 
tau and others3-5. Many of these proteins also cause disruptions in autophagy6, 7, raising the 
possibility that their ability to hinder autophagy contributes to their toxicity. In further support 
of a relationship between autophagy and neurodegenerative disease, some risk genes linked 
to neurodegenerative diseases play a role in the autophagy pathway1, 8.  This considerable 
body of evidence linking autophagy and neurodegeneration gives rise to the possibility that 






Understanding the interplay between autophagy and neurodegeneration requires a 
knowledge of the multiple steps and regulatory pathways involved in the autophagy pathway. 
The process of autophagy involves a series of regulated mechanical steps, including 
autophagosome formation, maturation and closure2, 9. The initial stages of autophagy are 
marked by cup-shaped, double-membraned phagophores, the formation of which requires 
PI(3)P generation by the Beclin-1-VPS34 complex10, 11. The edges of these phagophores 
subsequently extend and fuse to form autophagosomes12. These are trafficked towards the 
proximity of lysosomes via the dynein machinery on microtubules13, which allows fusion with 
lysosomes and degradation of autophagosomal contents. Each of these steps is subject to 
regulation by various upstream signalling pathways, notably via mTORC1, a major regulator 
of cell metabolism,14 and TFEB15, a key transcriptional regulator of autophagy and lysosomal 
biogenesis. Autophagic flux thus depends on multiple steps and requires coordination 
between autophagosome biogenesis and lysosomal degradation. Interventions aimed at 
inducing autophagy have been targeted towards various stages in this process, potentially 
leading to different effects on disease progression. 
This review will focus primarily on the potential of autophagy upregulation as a therapeutic 
strategy in several classes of neurodegenerative disease: Alzheimer’s disease (AD) and 
tauopathies, Parkinson’s disease (PD), polyglutamine diseases, and amyotrophic lateral 
sclerosis (ALS). Although most instances of neurodegenerative disease are sporadic, a small 
number of cases in each disease have been associated with disease-causing mutations in 
critical genes. These cases have allowed for the generation of important insights into the 
pathogenesis of each disease and are used in many of the cell and animal models of each 
illness. In each section, we briefly explore how proteins linked to the relevant disease impact 
autophagy. Subsequently, we describe the evidence in cells and in vivo models on whether 
autophagy induction may be of therapeutic value. Thorough reviews have previously been 
published on the pathogenesis of each of the described neurodegenerative diseases16-19 and 




Alzheimer’s disease and tauopathies 
AD is a neurodegenerative disease clinically characterized by progressive dementia and 
cognitive impairment. The pathology of AD is defined by the presence of two main hallmark 
elements: intracellular accumulation of neurofibrillary tangles (formed of hyperphosphorylated 
tau, a microtubule associated protein) and extracellular deposits of amyloid-β (Aβ) plaques 
arising from defective amyloid precursor protein (APP) processing. AD is the most common 
of the tauopathies, a class of neurodegenerative diseases characterised by pathological tau 
aggregation, including neuronal disorders such as frontotemporal dementias (FTDs), 
corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and primary age-
related tauopathy (PART)1, 20, 21.  
Defective autophagy in AD 
Autophagy plays a crucial role in continuously maintaining the homeostatic turnover of diffuse 
cytosolic proteins in neurons. Therefore, decreased autophagic flux results in impaired 
neuronal function and defects at different steps of the autophagy pathway may explain the 
pathology seen in AD and various tauopathies. While autophagy dysfunction may not be the 
principal cause of neurodegeneration, it may contribute to disease progression and pathology 
as a consequence of impaired turnover of toxic substrates in neurons. Two main defects in 
autophagy have been implicated in the pathogenesis of AD: impaired autophagosome 
synthesis22 and reduced clearance of autophagic substrates8, 22, 23. 
Decreased Beclin-1 levels result in reduced autophagic activity and have been associated 
with aging and neurodegeneration21, 24. Affected brain regions from patients with AD were 
shown to have decreased Beclin-1 mRNA expression and protein levels, which may explain 
the reduced autophagosome formation correlated with this disease22. Beclin-1 protein levels 
may be additionally decreased as a consequence of caspase 3 activation in the brain of AD 
patients25. Recent studies also identified reduced expression of the chaperonin CCT/TRiC 




its proper folding), CCT is essential for optimal autophagy-lysosomal activity by maintaining 
the physiological cell cytoskeleton structure in mouse primary neurons27. When CCT activity 
is impaired, the consequent reduction in autophagy flux results in accumulation of aggregate- 
prone proteins such as p62, Ataxin-3 or mHTT27. 
Genome-wide association studies identified risk loci and variants in PICALM to be associated 
with Alzheimer’ disease, and biochemical assessment of AD patient brains showed 
accelerated cleavage and consequent loss of function of PICALM28, 29. PICALM depletion 
impairs the endocytosis of VAMP2 and VAMP3 (SNAREs involved in the fusion of 
autophagosome precursors) as well as VAMP8 (involved in autophagosome-lysosome/late 
endosome fusion events)30. This consequently reduces both autophagosome biogenesis and 
fusion with lysosomes, leading to tau accumulation8, 30. 
Mutations of presenilin-1 (PS1) cause early-onset familial Alzheimer’s disease, and there is 
substantial evidence showing that these mutations impair autophagosome degradation via 
lysosomal V-ATPase dysfunction in patient-derived cells31. Apart from being part of the γ-
secretase complex and functioning in Aβ cleavage, PS1 acts as an ER chaperone for the V-
ATPase subunit VoA1 required for lysosomal acidification and autophagic turnover31. 
Abnormally increased levels of acid sphingomyelinase in the brains and fibroblasts of AD 
patients result in reduced TFEB levels due to proteolysis32. Chemical inhibition of this enzyme 
with amitriptyline in an APP/PS1 mouse model of AD improved autophagosome turnover and 
delayed disease development8, 32. In addition, several genetic risk factors for AD, such as the 
APOE4 variant and pathogenic mutations or duplication of APP, have been found to 
upregulate Rab5 and endocytosis23, 33-36. This causes overloading of the swollen lysosomes 
with proteins and lipids and reduced clearance of autophagic cargo. Indeed, AD mouse 






Autophagy inducers in Alzheimer’s disease 
The significant evidence linking autophagy and tauopathies has generated interest in 
developing autophagy-based therapeutics, and studies so far have indicated promising 
therapeutic potential in Alzheimer’s disease and various tauopathies5, 39, 40. Autophagy 
stimulation may be performed either chemically using small molecule enhancers of autophagy 
or through gene therapy approaches. Here we will summarise the results reported in different 
models of various autophagy-enhancing therapeutics. 
Small molecule enhancers of autophagy may be split in two main categories based on their 
mechanism of action: mTOR-dependent or mTOR-independent1, 21, 39. The first category of 
autophagy-inducing compounds is composed of mTOR inhibitors, including rapamycin and 
other rapalogs. These compounds were shown to provide beneficial effects in animal models 
of AD and other neurodegenerative tauopathies1. More specifically, both rapamycin and 
temsirolimus (a rapalog) enhanced the neuronal autophagic clearance of 
hyperphosphorylated tau and consequently rescued the spatial learning and memory 
impairments in P301S mutant tau transgenic mice41, 42. Similarly, long-term reductions in 
mTOR signalling lowered the levels of Aβ and improved cognitive function in the well-defined 
transgenic PDAPP mouse model of AD43. Rapamycin also reduced toxicity and increased 
survival to adulthood in Drosophila expressing wild-type or mutant variants of tau (R406W), 
effects accounted for by an autophagy-dependent reduction in insoluble tau levels44. Indeed, 
treatment with rapamycin or other rapalogs decreased only the insoluble form of tau in COS-
7 cells expressing the most common tau mutation (P301L), or SH-SY5Y cells incubated with 
okadaic acid41, 44.  
The second group of chemical compounds enhances autophagy independently of mTOR and 
comprises a continuously expanding list of molecules. One of those molecules, trehalose, a 
naturally occurring disaccharide that acts as a “chaperone” by assisting proper protein folding 
through direct protein-trehalose interactions, has been shown to induce autophagy through 




(also known as GLUT)45-47. Trehalose treatment enhanced the clearance of tau aggregates 
and reversed the dropout of dopamine neurons in an autophagy-dependent manner in several 
transgenic in vivo models of tauopathies, including a mouse model expressing the human 
mutant P301S tau and a mouse model of tau overexpression with Parkinsonism5, 48. 
Interestingly, pharmacological doses of melatonin, a neurohormone that activates AMPK, 
were recently reported to restore autophagy flux and prevent cognitive decline in mouse 
models of tauopathies49. Another small neuroprotective peptide, humanin, identified initially 
from a cDNA library of AD patients50, is able to decrease Aβ deposition in the brain of APP/PS1 
transgenic mice in an autophagy-dependent fashion51. Activation of autophagy by humanin 
occurs via reducing neuronal insulin resistance via IRS-1 signalling inhibition and AMPK 
activation. 
Other AMPK modulators, such as metformin, nilotinib or bosutinib, have been reported to have 
beneficial effects in the transgenic APPswe/PS1ΔE952 and TgAPP mouse models53, 54. Early 
results from pilot clinical trials of metformin in AD appear promising, although they require 
further validation from larger studies. One randomised placebo-controlled trial of metformin in 
amnestic mild cognitive impairment (aMCI) demonstrated a small beneficial effect on total 
memory recall55, and another crossover study demonstrated an association with improved 
executive functioning56. However, some studies have found that autophagy activation by 
metformin, nilotinib or bosutinib causes secretion of Aβ into the extracellular space and 
promotes amyloidogenic APP processing by γ-secretase in autophagosomes in Tg6799 
mice57 and Apoliprotein E deficient (ApoE-/-) mice58. Other pathways unrelated to protein 
clearance may thus important to consider when evaluating the potential efficacy of a therapy. 
Another group of compounds known to upregulate autophagy and enhance clearance of 
autophagic substrates comprises a class of mood stabilizing drugs, including lithium46, 59. 
Lithium administration impairs phosphoinositol signalling via cellular depletion of inositol by 
impairing IP3 recycling. Reduced IP3 levels lead to decreased levels of Ca2+ in the cytoplasm 




activation of AMPK, which directly phosphorylates ULK1 and induces autophagy60. Lithium 
additionally upregulates autophagy by inhibiting GSK3β activity and reduces tau 
phosphorylation and amyloid production in pre-pathological AD mouse models 
(AβPPswe/PSA1A246E)61. Recent studies strengthen the relevance of the GSK3β-autophagy 
axis in AD, as pharmacological inhibition of GSK3β (using the inhibitor SB216763) upregulates 
the expression of TFEB and other autophagy genes, and thereby restores lysosomal function 
in PS1-knockout or -mutant neurons62. Activation of other autophagy-related transcription 
factors, such as the nutrient-sensing nuclear receptors PPARα, with relevant agonists 
(gemfibrozil or Wy14643) increased Aβ clearance and rescued the cognitive deficits in 
APP/PS1ΔE9 mice63. 
Initial data from clinical trials relating to the use of lithium in AD has revealed some promising 
results. One clinical trial investigating the efficacy of lithium as a neuroprotective agent in 
patients with AD-associated mild cognitive impairment reported positive findings, with lithium-
treated patients displaying reduced cognitive decline over a two-year period compared to the 
placebo group64. This attenuation of decline was associated with increased amyloid-beta 
peptide in the CSF, which may reflect clearance of Aβ from the brain. It may be interesting to 
investigate this data in connection with the aforementioned Aβ secretion into the extracellular 
space on some instances of autophagy induction57. Other clinical trials have shown no effects 
on disease markers65, 66, although these negative findings may in part be due to the small 
sample sizes and short treatment durations used in these trials. 
Multiple screens of FDA-approved drugs have identified new mTOR-independent modulators 
of autophagy, which include imidazoline receptor agonists, L-type Ca2+ channel antagonists 
and calpain inhibitors46, 67. The first class of drugs is comprised of imidazoline receptor 
agonists such as clonidine and rilmenidine. While these drugs are extensively used as anti-
hypertensive agents in humans with no significant side effects, they are also known to induce 
autophagy by decreasing intracellular cAMP levels67-69. The beneficial effects of clonidine and 




mutant tau coupled to the green-to-red photoswitchable fluorescent protein Dendra40. The rare 
p.A152T variant of tau is a genetic risk factor for the tauopathy progressive supranuclear palsy 
(PSP)40, 70. Indeed, treatment with either imidazoline receptor agonist increased the clearance 
of mutant tau and ameliorated the abnormal morphological and motor defects seen in 
untreated A152T tau fish40. 
The second class of compounds, the L-type Ca2+ channel antagonists (felodipine and 
verapamil), block the influx of extracellular Ca2+ and thus decrease intracellular Ca2+ levels 
and mitochondrial Ca2+ uptake. This leads to lower ATP production followed by AMPK 
activation, which directly phosphorylates ULK1 and enhances autophagy in mouse primary 
neurons and in vivo models of tauopathies60, 71. These two drugs were tested in two transgenic 
zebrafish models expressing either mutant A152T tau pan-neuronally or wild-type human tau 
in rod photoreceptors only71. Both drugs, via an autophagy-dependent mechanism, 
ameliorated the abnormal morphological phenotype and significantly reduced the levels of 
insoluble tau species in these fish models. Elevated levels of intracellular Ca2+ can also 
activate the Ca2+-dependent cysteine proteases (calpains), which impair autophagy. Chemical 
inhibition of calpains with calpastatin (the endogenous calpain inhibitor), calpeptin or genetic 
knockdown, has the opposite effect of stimulating autophagy67. Indeed, studies using the 
calpain inhibitor A-705253 showed beneficial effects in clearing Aβ and hyperphosphorylated 
tau with improved cognition in transgenic 3xTg-AD mice harbouring mutations in three genes, 
PS1(M146V), APP(swe) and Tau(P301L)72. 
Genetic approaches in Alzheimer’s disease 
The aforementioned pharmaceutical compounds offer clear evidence that autophagy 
upregulation is beneficial for AD in in vivo models. However, one should account for their 
possible side effects when translating these potential therapeutic strategies in humans, as 
these chemicals likely have additional signalling targets independent of the autophagy 
pathway. One potential strategy to overcome these unwanted effects is the use of gene 




Lentiviral-induced Beclin-1 expression, one of the most common strategies to stimulate 
autophagy by gene therapy, was shown to reduce both intracellular and extracellular amyloid 
pathology in the hippocampus and cortex of APP transgenic mice22. An elegant approach 
using a knock-in point mutation F121A in Beclin-1, which prevents the Beclin-1 interaction with 
its inhibitor BCL2, led to hyperactivation of autophagy with a consequent significant decrease 
in Aβ levels and restoration of survival in 5xFAD mice (expressing a combination of five familial 
AD (FAD) mutations in human APP and PS1 genes)73. Beclin-1-mediated autophagy may also 
be stimulated by lentiviral Parkin transduction, promoting clearance of damaged mitochondria 
and intracellular Aβ degradation in a triple transgenic AD mouse model (3xTg-AD) expressing 
the PS1(M146V), APP(swe), Tau(P301L) and knock-in mutations74. 
Overexpression of another essential autophagy gene, Atg5, induces autophagy and 
ameliorates the abnormal morphological defects in an A152T-tau zebrafish model40. 
Intriguingly, deletion of Atg7 in APP transgenic mice results in reduced Aβ plaque deposition 
as a consequence of reduced Aβ secretion into the extracellular space75. Similarly to 
pharmacological inhibition, knockdown of calpain or calpastatin overexpression are protective 
against tau toxicity in multiple in vivo models of tauopathies76, 77.  
For many tauopathies, upregulation of autophagy may be an attractive therapeutic strategy – 
successful autophagy induction and improved neurodegeneration phenotypes were seen in 
various in vivo models1, 39, 78. However, diseases with impairment in the late stages of 
autophagy and lysosomal functioning may not benefit from further activation of autophagy. In 
these cases, overexpression of genes such as BECN1 and ATG5 that mainly induce 
autophagosome synthesis with little effect on lysosomal function may potentially only lead to 
unproductive accumulation of autophagosomes. A promising therapeutic approach for 
complex diseases like AD may be to enhance the overall autophagic flux by acting on different 
steps in the autophagy pathway. Therefore, an interesting target for drug development may 




biogenesis1, 15. Indeed, overexpression of TFEB was beneficial in reducing neurofibrillary 








Parkinson’s disease (PD) is a debilitating neurodegenerative disorder primarily characterised 
by progressive loss of motor control and, in many cases, cognitive decline. These symptoms 
are the result of the death of dopaminergic neurons in the substantia nigra pars compacta, 
and are associated with the accumulation of intraneuronal protein aggregates (Lewy bodies), 
predominantly comprised of α-synuclein (α-syn)80. A large body of evidence implicates 
defective autophagy as central to both the aetiology and pathogenesis of Parkinson’s disease, 
and numerous genetic mutations encoding components of the autophagic machinery or 
relevant to the autophagy-lysosomal pathway (ALP) have been identified as disease risk 
factors81, 82. Both autophagosome biogenesis and autophagosome-lysosome fusion appear to 
be compromised in PD neurons81, and so induction of macroautophagy has received much 
attention as a therapeutic strategy to ameliorate the toxic effects of α-syn accumulation. 
A wealth of research implicates the intrinsically disordered protein α-syn as a significant 
contributor to autophagic deregulation and PD pathogenesis. Overexpression of α-syn is 
sufficient to induce the accumulation of filamentous protein inclusions, the death of 
dopaminergic neurons, and locomotor abnormalities in animal models83, 84, and multiplication 
of the gene encoding α-syn causes autosomal dominant disease in humans85. Two extensively 
studied missense mutations in the α-syn gene, A53T and A30P, also cause autosomal 
dominant early onset Parkinson’s86, 87. For these reasons, much effort has been expended in 
the search for long-term therapies that enhance the clearance of intraneuronal α-syn. 
Experimental evidence points to roles for both the ubiquitin-proteasome system (UPS)88, 89, 
and the ALP in the degradation of wild-type (WT) α-syn4. Because WT α-syn contains the 
chaperone-mediated autophagy (CMA)-targeting motif, CMA is a major contributor to 
autophagic degradation of α-syn90. However, in cases of intracellular α-syn accumulation, 
where CMA is often disrupted91, macroautophagy is thought to take on a more significant 




WT α-syn oligomers92, 93, A53T mutant α-syn (which has a higher propensity to aggregate)94, 
and post-translationally modified α-syn 95. 
Defective autophagy in Parkinson’s disease 
The overexpression or accumulation of α-syn specifically disrupts the process of 
macroautophagy via a number of different mechanisms, blocking the degradation of 
autophagic substrates including α-syn itself. Increased intracellular levels of pathogenic α-syn 
can lead to Rab1a-mediated mislocalisation of the autophagy protein Atg9, inhibiting 
autophagosome biogenesis96. The D620N mutation in the vacuolar protein sorting-associated 
protein 35 (VPS35), which causes an autosomal dominant form of PD, is thought to result in 
a similar defect in ATG9 trafficking97, although this may not be the only factor contributing to 
the mutation’s pathogenicity98. The observations that α-syn accumulates in autophagosomes 
but not lysosomes in post-mortem PD brains99, and that the presence of α-syn aggregates 
inhibits autophagosome maturation and fusion with lysosomes in vivo100, suggest that 
autophagic flux may also highly compromised by α-syn accumulation. Lysosomal function may 
be impaired by mutant α-syn, α-syn oligomers, or post-translationally modified α-syn, which 
are all poorly translocated into the lysosomal lumen94. Deficient autophagy is particularly 
disadvantageous for neuronal cells due to their post-mitotic nature, and can result in cell death 
due to oxidative stress101, or from the lack of clearance of damaged organelles, such as 
mitochondria102. 
Other genes associated with PD risk have also been linked to autophagy. Mutations in the 
acid β-glucocerebrosidase (GBA1) gene are a strong genetic risk factor for PD103. iPSC-
derived neurons from PD patients with mutations in GBA1 show autophagic and lysosomal 
defects, including an accumulation of lysosomes, impairment of lysosomal hydrolytic function, 
and impaired fusion between autophagosomes and lysosomes81. Additionally, the PD-




TFEB104. Depletion of ATP13A2 appears to decrease levels of SYT11 via both transcriptional 
and post-translational mechanisms, and disruption of the pathway blocks autophagy104. 
Autophagy inducers in Parkinson’s disease 
Rapamycin - an allosteric mTORC1 inhibitor105 - is one of the most frequently studied 
macroautophagy inducers, and has been shown to increase the clearance of WT, A30P, and 
A53T α-syn in PC12 cells4, and to attenuate neuronal toxicity in dopaminergic neurons106. 
Beneficial effects have also been observed in vivo; rapamycin reduced α-syn accumulation in 
transgenic α-syn mice107, protected against MPTP-induced neuronal death in WT-mice108, and 
improved motor function in A53T transgenic mice109. In addition to stimulating autophagosome 
biogenesis105, it has been proposed that rapamycin may increase lysosomal biogenesis106, 
thus potentially avoiding autophagosome accumulation and neuronal toxicity. It is noted that 
ATP-competitive mTOR inhibitors such as Torin-1 may be less suited for therapeutic purposes 
as they target both mTORC1 and mTORC2, as well as PI3K in some cases, and so induce 
neuronal toxicity on chronic administration110, 111.  
A number of mTOR-independent autophagy inducers have also shown beneficial effects in 
PD models. Three novel small-molecule enhancers of rapamycin (SMERs) — SMER10, 
SMER18, and SMER28 - were identified by a chemical screen, and were shown to induce 
autophagic clearance of A53T α-syn in vitro in an mTOR-independent manner112. The exact 
mechanisms by which each SMER exerts their effects on α-syn have yet to be determined113. 
The AMPK modulator trehalose enhances the clearance of A53T and A30P α-syn in 
doxycycline-inducible PC12 cell lines, but not the clearance of WT α-syn, which in these 
models was likely not strongly dependent on macroautophagy for its clearance45. In vivo 
studies have demonstrated similar autophagy-dependent results; oral administration of 
trehalose protects against tyrosine hydroxylase and dopamine transporter loss and reduces 
neuroinflammation in an MPTP induced PD mouse model114, and additionally prevents deficits 




model115. Trehalose treatment also decreases Akt activity, thereby activating the transcription 
factor TFEB and consequently the expression of autophagy and lysosomal genes116. A study 
which trialed the combined use of trehalose and the mTOR-dependant autophagy enhancer 
rapamycin in an MPTP-induced mouse model of PD further suggests that an additive effect 
may result from stimulating autophagy via different pathways117. Combined treatment in this 
case was more efficacious than either compound alone in reducing dopaminergic deficits and 
restoring expression of tyrosine hydroxylase, but did not improve cognition more than 
trehalose alone117.  
A number of other AMPK-dependent autophagy inducers already in use for various clinical 
purposes have shown promise in cell and animal models of PD. Metformin (a drug currently 
used in the treatment of type 2 diabetes) induced a reduction in the levels of Ser-129 
phosphorylated α-syn in α-syn overexpressing SH-SY5Y cells118, partially rescued 
mitochondrial dysfunction in genetic Drosophila models of PD119, and appeared 
neuroprotective in MPTP mice120. Nilotinib, a tyrosine-kinase inhibitor approved for use 
treating chronic myelogenous leukaemia, stimulated autophagy and partially rescued disease 
phenotype in both A53T and lentiviral α-syn overexpression PD mouse models via inhibition 
of phosphorylation of BCR-ABL121-123. A Phase 1 human clinical trial of nilotinib in PD patients 
with cognitive impairment showed improvements in cognitive and motor skills at doses of 150 
mg and 300 mg124.  Phase 2 trials are currently ongoing and have so far generated promising 
results124. The natural plant phenol resveratrol was shown to induce AMPK-dependent 
autophagy and α-syn clearance in SH-SY5Y and PC12 cells, possibly via interaction with 
SIRT1125, 126. It also reduced the incidence of apoptosis in SH-SY5Y neuroblastoma cells 
exposed to rotenone127, protected against reactive oxygen species (ROS) in 6-
hydroxydopamine (6-OHDA)-induced rat PD models128,129, and appeared to be anti-
neuroinflammatory in an MPTP mouse PD model130.  
Corynoxine B, an oxindole alkaloid isolated from a herb used in traditional Chinese medicine, 




cortical neurons131. This led to enhanced clearance of WT, A53T, and A30P α-syn monomers 
in differentiated dopaminergic neurons, and of α-syn oligomers and α-syn/synphillin-1 
aggrosomes in N2a cells. The mechanism of autophagy induction was found to be mTOR-
independent, but appears to be mediated by Beclin-1131. In cells subject to accumulation or 
overexpression of α-syn, cytosolic translocation of HMGB1 is blocked, inhibiting the reaction 
between Beclin-1 and HMGB1 and thereby suppressing autophagy132. There is some data to 
suggest that corynoxine B can, under these same conditions, rescue the cytosolic localisation 
of HMGB1, thus rescuing the autophagy defect133. Corynoxine, an enantiomer of corynoxine 
B, was also shown to induce autophagy in SH-SY5Y and PC12 cell lines and to enhance the 
clearance of WT and A35T α-synuclein, but interestingly via a different, Akt/mTOR dependent 
mechanism134. 
The mTOR-independent autophagic inducer lithium enhanced the clearance of A53T and 
A30P mutant α-syn in inducible PC12 cell models59, protected SH-SY5Y neuroblastoma cells 
from rotenone induced toxicity135, and appeared to reduce Parkinsonian phenotypes in an 
aged Parkin mutant transgenic mouse model136. In addition to the aforementioned IP3-
dependent mechanism of autophagic induction, lithium may also act via inhibition of the 
GSK3β pathway. Activation of GSK3β, an autophagy inhibitor, has been observed in α-syn 
overexpression and MPTP models of PD, as well as in postmortem striatum of PD patients, 
and appears to be dependent on the presence of α -syn137. Inhibition of GSK3β activity by 
lithium increases TFEB levels, and likely contributes to the compound’s autophagy enhancing 
effects137. Other mood-stabilising drugs have also been studied as potential autophagy 
inducers, and two – sodium valproate and carbamazepine – have been shown to induce 
autophagy and mimic the neuroprotective properties of lithium in SH-SY5Y cells exposed to 
rotenone138 through an inositol-dependent mechanism. It has been reported that, as in the 
case of trehalose/rapamycin combination therapy, concomitant treatment of PC12 cells with 
lithium and rapamycin had an additive effect on the clearance of A53T α-syn139, while 




mouse PD model140. It is necessary to note that most known mood stabilising drugs affect 
multiple cellular processes, and as such may not be ideal therapeutic candidates.  
Genetic approaches in Parkinson’s disease 
There is evidence to suggest that α-syn accumulation may sequester the transcription factor 
TFEB in the cytoplasm, preventing its translocation into the nucleus and blocking its 
transcriptional activity141. This hypothesis is supported by the observations that nuclear TFEB 
levels were significantly reduced in the post-mortem PD midbrains, and that TFEB co-localised 
with filamentous α-syn inclusions in neurons containing Lewy bodies142. While the extent to 
which TFEB is implicated in the pathogenesis of PD is still unclear, overexpression of TFEB 
has been shown to protect dopaminergic neurons from toxicity induced by AAV vector-
mediated overexpression of human α-syn in the rat midbrain, and to protect against 
behavioural abnormalities in the same transgenic rat model142. Lentiviral overexpression of 
Beclin-1 also reduces α-syn aggregation and ameliorates disease symptoms in a transgenic 
PD mouse model143.  
Upregulation of autophagy represents an attractive therapeutic strategy in the treatment of 
PD, with phenotypic improvements observed in a number of in vivo and in vitro disease 
models. However, mutant, post-translationally modified, and oligomerised α-syn negatively 
impact multiple distinct stages of the autophagic pathway, including lysosomal function. 
Therapies designed to stimulate autophagic flux, such as those targeting TFEB or combination 
therapies, may restore intraneuronal homeostasis without causing the accumulation of 











There are currently nine known diseases caused by polyglutamine expansion mutations: 
Huntington’s disease (HD); spinal and bulbar muscular atrophy (SBMA); 
dentatorubropallidoluysian atrophy (DRPLA); and spinocerebellar ataxia (SCA) types 1, 2, 3, 
6, 7, and 17144. These mutations are encoded by the expansion of a (CAG)n trinucleotide 
repeat tract in the relevant proteins. For example, in HD up to 35 CAGs are well-tolerated and 
considered within the range of normal variation, while 36 or more repeats cause disease. The 
mutant proteins cause disease via toxic gain-of-function mechanisms. 
Defective autophagy in polyglutamine diseases 
As aggregate-prone proteins containing polyQ expansions are substrates of autophagy, 
disruptions in the autophagy pathway may contribute to an accumulation of the relevant 
proteins and consequent toxicity. Additionally, recent studies have revealed that some of the 
genes associated with polyQ disease are themselves important regulators of autophagy in 
their wild-type forms. This suggests that disease pathology may be in part due to a direct 
inhibition of autophagy, rather than simply overwhelming the natural autophagic machinery 
with misfolded proteins8.  
Wild-type HTT itself appears to play a complex and incompletely understood role in the 
autophagy pathway, and polyQ-expanded mutant huntingtin (mHTT) has been reported to 
impact autophagy in different ways. mHTT appears to impede cargo recognition145 by 
autophagosomes, which will slow substrate degradation. Interestingly, recent studies have 
proposed that wild-type HTT may act as a scaffold for selective autophagy146, 147. This raises 
the possibility that disruption of the native function of wild-type HTT by mHTT may contribute 
to disruption of cargo recognition in HD, although the precise mechanisms remain to be 
elucidated. Interestingly, expression of full-length HTT lacking its polyglutamine stretch (ΔQ-




truncated N-terminal mHTT aggregates148. As overexpression of full-length wild-type HTT in 
vitro does not increase autophagosome synthesis, this may represent a gain-of-function effect. 
Additionally, polyQ-expanded proteins may cause defects in neuronal vesicular trafficking149. 
In neurons, autophagosomes are constitutively formed in the axon terminal and are trafficked 
by the microtubule motor-protein dynein towards the cell body after maturation150. Dynein 
mutations are linked to decreased clearance and increased toxicity of mutant HTT in flies and 
mice151, and polyQ proteins inhibit both anterograde and retrograde fast axonal transport in 
isolated axoplasm without the presence of aggregates152. Since this occurs without 
transcription or translation, this defect is likely due to direct protein-protein interactions. 
Interestingly, silencing of either wild-type HTT or its interactor, HTT-associated protein 1 
(HAP1), was found to block retrograde transport of autophagosomes along axons153. The 
effect of HTT on retrograde transport appeared to be dependent on an interaction between 
HTT and dynein153, 154. It is thus possible that polyQ-expanded HTT also disrupts autophagy 
by interfering with the function of wild-type protein. By impairing autophagosome and 
lysosome trafficking, polyQ-expanded proteins may inhibit their own degradation, leading to a 
positive feedback loop.  
PolyQ-expanded proteins may also interfere with elements of the autophagy machinery. Wild-
type Ataxin-3 has been shown to deubiquitinate Beclin-1, a critical component of 
autophagosome nucleation and maturation155, thereby protecting it from proteasomal 
degradation7. Interestingly, the polyQ tract in Ataxin-3 is the structural motif facilitating this 
interaction, representing a novel binding mechanism7. In fibroblasts derived from patients with 
HD, SCA3, or DRPLA, the longer polyQ tracts in the disease protein outcompete wild-type 
Ataxin-3 for this binding site, resulting in increased Beclin-1 degradation and consequently 
impaired starvation-induced autophagy7.  
Some polyQ disease proteins may also disrupt the expression of autophagy and lysosomal 




as evidenced by nuclear translocation of both following the addition of an androgen ligand to 
cell culture media, but this coactivation is lost in the polyQ-expanded AR that causes SBMA156. 
When in the nucleus, TFEB stimulates the CLEAR network of genes which increases 
lysosomal biogenesis157, and SBMA neurons exhibit a build-up of autophagosomes consistent 
with a block in degradation. This can be rescued by overexpression of TFEB, suggesting 
alternative activation of TFEB as a clinical strategy. DRPLA is caused by a polyglutamine 
expansion in atrophin-1 (ATN1). PolyQ-expanded ATN1 mice were found to exhibit reduced 
autophagic flux characterized by a block in degradation and inactivation of TFEB158. 
Furthermore, late-stage DRPLA appears to have impaired autophagosome degradation in 
flies159.  
Autophagy inducers in polyglutamine diseases 
The presence of dense inclusion bodies containing the relevant polyQ-expanded proteins in 
post-mortem HD tissue initially led to the theory that protein aggregation was the prime driver 
of cytotoxicity. This theory was supported by in vitro studies which noted that long 
polyglutamine tracts destabilize peptide structure and cause proteins to be prone to 
aggregation160. Regardless of which species of protein is the most toxic, reducing the total 
pool of mutant protein ameliorates disease in cells, and autophagy upregulation has the 
potential to reduce the levels of both oligomers and aggregates. Since polyQ-expanded 
proteins are preferentially degraded by autophagy in cell models161 and inducing autophagy 
with rapamycin or other small molecules reduces the toxicity of polyQ-expanded huntingtin 
fragments in cells, flies, and mice3, 67, 112, 139, it has thus been a longstanding idea that inducing 
autophagy prior to pathogenesis would be a viable strategy for postponing or preventing 
disease onset. The clearance of polyQ-expanded proteins by autophagy is particularly critical 
as polyQ aggregates may impair clearance by the proteasome162. 
Autophagy enhancers from many different classes have been shown to be beneficial in cells 




fragments in cells and mice3. Trehalose, a mTOR-independent autophagy inducer, has been 
found to increase motor function and lifespan in transgenic mice expressing mHTT163. The 
mTOR-independent small molecules SMER10, SMER18, and SMER28 similarly reduce 
mHTT toxicity in cells and Drosophila112. Combination therapy using rapamycin and lithium 
appears to provide greater protection against neurodegeneration in fly models, and thus 
combining mTOR-dependent and mTOR-independent enhancers may be a therapeutic option 
to explore164. 
Additionally, the mTOR-independent small molecules loperamide, nimodipine, minoxidil, and 
rilmenidine were all found to ameliorate mHTT aggregation and toxicity in an autophagy-
dependent manner in cells, as well as verapamil, clonidine, and calpastatin in both cells and 
zebrafish models67, 165. Specifically, verapamil is an antagonist of the L-type Ca2+ channel, 
loperamide is an opioid receptor agonist, minoxidil opens the K+ATP channel, rilmenidine and 
clonidine are inhibitors of the imidazoline receptor, and calpastatin is a calpain inhibitor. 
Despite affecting such diverse targets, each of these drugs influence a common pathway 
which, when activated, increases cytoplasmic Ca2+ and cAMP levels and inhibits autophagy139.  
The search for novel autophagy inducers has yielded other interesting modulators. Nitric oxide 
(NO), a key signalling molecule, has been found to inhibit autophagosome synthesis via 
multiple pathways. These include inhibition of JNK1, which reduces phosphorylation of Bcl-2 
and thereby enhances its inhibitory interaction with Beclin-1. NO also inhibits IKKβ, which 
leads to a reduction in AMPK phosphorylation and activity. Depletion of NO via inhibitors of 
nitric oxide synthase increases autophagic flux and consequently ameliorates pathology in HD 
models166. Another study aiming to identify potent neuronal inducers of autophagy yielded a 
N10-substituted phenoxazine that, at proper doses, potently and safely up-regulated 
autophagy in neurons in an Akt- and mTOR-independent fashion167. Modulation of autophagy 
using CTEP, a negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), 




appeared to be mediated through an autophagy pathway mediated by GSK3β, ZBTB16, and 
ATG14. 
For SBMA, anti-androgen treatment has also been a longstanding strategy ever since 
castrated mice were found to have reduced symptoms and improved lifespan169, and 
transgenic flies were found to only exhibit neurodegeneration upon treatment with androgen 
ligand, which was lost when the AR was trapped in the cytosol170. These findings suggest that 
nuclear translocation is a critical step in the pathogenesis of SBMA. Nuclear polyglutamine 
aggregates may not be as accessible to autophagy, which may contribute to their toxicity171. 
Further, treatment with direct AR antagonists such as enzalutamide and flutamide reduces 
toxicity in SBMA mice, co-treatment with autophagy inducers further decreases toxicity, and 
inhibiting autophagy increases toxicity172-174.  
Genetic approaches in polyglutamine diseases 
Several genetic interventions targeting autophagy have also been shown to have beneficial 
effects in cell and animal models of HD. Overexpression of constitutively active AMPK-α as 
well as treatment with the AMPK activator A769662 induces autophagy, reduced aggregation, 
and improved cell viability in STHdh cells and mouse embryonic fibroblasts175. Overexpression 
of Rab5, which complexes with Vps34 and Beclin-1 was also found to enhance 
autophagosome formation and attenuate toxicity in cell and Drosophila models of HD176. 
Genetic ablation of XBP1 also appears to increase mHTT clearance and ameliorate HD 
pathology in cell and mouse models of HD177. This effect appears to occur via a mechanism 
involving autophagy, as depletion of XBP1 increased levels of FOXO1 and consequently the 
transcription of autophagy-related genes. In a mouse model of HD, restoration of PGC-1α 
(which is inhibited by mHTT) reduced mHTT aggregation and ameliorated disease symptoms 
via a pathway involving the activation of TFEB178. Finally, the deubiquitinase Usp12 was 




patients and rodent models as well as in Drosophila, overexpression of Usp12 increased 
autophagic flux and rescued mHTT neurotoxicity in an autophagy-dependent manner179. 
Interestingly, expression of full-length HTT lacking its polyglutamine stretch (ΔQ-htt) in a 
knockin mouse model for HD (Hdh140Q/ΔQ) significantly reduces levels of mHTT aggregates, 
ameliorates neurological defects, and extends lifespan in comparison to HD model mice 
(Hdh140Q/+)148. This was found together with an increase in steady-state levels of the 
autophagic marker LC3-II, suggesting that the beneficial effects may be due to an increase in 
autophagy. In support of this, overexpression of ΔQ-htt in cells was shown to increase 
autophagic clearance. Furthermore, HdhΔQ/ΔQ mice (expressing only ΔQ-htt without polyQ-
expanded htt) show a significant increase in lifespan in comparison with WT mice, suggesting 
that the increase in autophagy caused by ΔQ-htt may also have effects on longevity in normal 
mice. 
Induction of more specific forms of autophagy may also be of therapeutic benefit in HD. One 
element of HD pathology appears to be impaired clearance of defective mitochondria.180 
Overexpression of PINK1, a critical mitophagy gene, alleviated mitochondrial pathology, ATP 
levels, neuronal integrity and adult fly survival in a genetic Drosophila model of HD180. 
Genetic induction of autophagy has also been tested in other polyglutamine diseases. 
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is an 
autosomal dominant disease caused by a polyQ expansion in the Ataxin-3 gene. In 
neuroblastoma and rat models of SCA3, lentiviral overexpression of Beclin-1 increased 
autophagic flux, increased the clearance of mutant Ataxin-3, and appeared to reduce neuronal 
pathology in the striatum of the rat model181. A subsequent study of lentiviral Beclin-1 
overexpression in a transgenic SCA3 mouse model showed similar marked improvements in 
aggregate clearance and neuropathology, and additionally demonstrated significant 




Together, these data suggest that polyQ diseases are amenable to activation of autophagy 
via a variety of pathways and using a variety of drugs. Because polyQ diseases may be 
diagnosed presymptomatically, a prospective therapeutic strategy may be to begin treatment 




Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which is 
characterized by progressive degeneration of upper and lower motor neurons. The majority 
(~90%) of ALS cases are sporadic, and only 5-10% of all cases have been reported to be 
familial183. A large number of pathogenic mutations within over 30 genes have been linked to 
ALS. The most commonly involved genes are superoxide dismutase (SOD1)184, fused in 
sarcoma (FUS)185, TAR DNA-binding protein 43 (TDP-43)186, sequestosome 1 
(SQSTM1/p62)187, 188, optineurin (OPTN)189, valosin-containing protein (VCP)190, TANK 
binding kinase 1 (TBK1)191, ubiquilin 2 (UBQLN2)192, dynactin subunit 1 (DCTN1)193, alsin 
(ALS2)194, profilin 1 (PFN1)195, charged multivesicular body protein 2B (CHMP2B)196, 197, 
factor-induced gene 4 (FIG4)198, and a hexanuleotide repeat expansion (GGGGCC) found in 
the C9orf72 gene199. Mutations in these genes affect multiple cellular pathways including 
protein quality control, axonal transport and RNA metabolism200. The abundance of ubiquitin-
positive inclusions is a characteristic neuropathological feature in ALS, indicating impairment 
of protein quality control systems. Interestingly, these inclusions were also found to be positive 
for mutant SOD1 and TDP-43 in transgenic mice and patients201-203.  
Defective autophagy in ALS 
Since many genes linked to ALS impact autophagy, it is believed that dysfunctional autophagy 
is one of the critical elements in the disease. Several of these genes encode various 
autophagy receptors, which are vital for the recruitment of specific cargo to autophagosomes 
for degradation204. These receptors share common domains such as a ubiquitin-associated 
domain (UBA) and a LC3-interacting region (LIR); the former enables binding to ubiquitinated 
substrates while the latter facilitates loading onto the developing phagophore205. Mutations in 
a number of autophagy receptors, including SQSTM1/p62, OPTN and UBQLN2, have been 




SQSTM1/p62 is found in ubiquitin-positive inclusions of mutant SOD1 (mSOD1) in motor 
neurons of ALS mouse models. Mutations in p62 are implicated in ALS, including an ALS-
linked L341V substitution mapped to the p62 LIR, which abrogates its interaction with LC3B 
and hence interferes with the loading of p62 onto the phagophore206. 
A number of mutations in OPTN are associated with both familial and sporadic cases of ALS189, 
207. These mutations include a homozygous deletion of exon 5, a homozygous Q398X 
nonsense mutation, and a heterozygous E478G missense mutation. The E478G mutation in 
the UBA of OPTN abolishes its interaction with ubiquitin but does not affect its capacity to 
interact with mutant SOD1 via its C-terminal coiled-coil domain. Also, downregulation of OPTN 
in a mutant SOD1 G93A zebrafish ALS model using morpholinos exacerbates motor 
axonopathy189, 208. Additional mutations in the UBA domain of OPTN, Q398X and E478G, 
impede autophagosome maturation, since these mutant forms cannot recruit MYO6, which 
facilitates fusion of autophagosomes to endosomes and ultimately degradation of 
autophagosomes209, 210. 
Ubiquilin 2 (UBQLN2) aids in the appropriate identification of ubiquitinated misfolded proteins 
by p62 through its UBA domain. Overexpression of the ALS-linked mutant P497H UBQLN2 
imparts a toxic gain of function in a rat model and causes defects in autophagy by disrupting 
endosomal pathways211. 
The ALS-associated gene ALS2, which encodes alsin, has also been found to impact 
autophagy. Alsin is a guanine nucleotide exchange factor for Rab5 and this interaction is 
mediated by the Vps9p domain of alsin. Genetic ablation of ALS2 in SOD1H46R mice 
exacerbated the disease phenotype by disturbing the cascade of autophagosome maturation 
and lysosomal fusion, as alsin has been shown to associate with p62 and LC3 to facilitate 
autophagic clearance by maintaining balanced endosomal fusion212,213. Moreover, 
simultaneous depletion of p62 and ALS2 in a mutant SOD1H46R mouse model aggravated 
disease, providing further evidence that both of these independent ALS-linked genes protect 




Common disease models of ALS show complex alterations to autophagy that remain 
incompletely understood. One widely used model is mutations in the SOD1 gene, which 
encodes a Cu-Zn superoxide dismutase that converts reactive superoxide radicals to 
hydrogen peroxide and oxygen in order to relieve oxidative stress in cells. Mutations in SOD1 
constitute almost 20% of familial cases of ALS, and are among the most widely studied genetic 
causes of the disease184. Early evidence indicated that transgenic SOD1G93A mouse model of 
ALS shows increased numbers of autophagosomes, compared with non-transgenic or human 
wild-type SOD1 transgenic animals215. As later studies have also found endolysosomal deficits 
and reduced substrate clearance in SOD1G93A mice, this increased number may be due to a 
block in autophagosomal degradation216. TDP-43 has also been found to positively regulate 
autophagy by stabilizing ATG7 mRNA in cells, and depletion of TDP-43 results in autophagy 
impairment and accumulation of aggregate-prone proteins217. Disruption to native TDP-43 
function in disease states (e.g. by sequestration in aggregates) may thus impair autophagy. 
A hexanucleotide (G4C2) repeat expansion in C9orf72 accounts for 25% of familial cases and 
10% of sporadic cases199 of ALS. Its contribution to ALS pathogenesis is multitudinous as the 
mutated RNA form can affect transcription of wild-type C9orf72, can accumulate in RNA foci 
inside the nucleus and can sequester RNA binding proteins such as TDP-43 and FUS. The 
translated products of G4C2 C9orf72 are toxic dipeptides which disrupt nucleocytoplasmic 
transport218, aggregate with p62219, and inhibit the proteasome220. Loss of C9orf72 inhibits 
initiation of ULK1-mediated autophagy by disrupting the SMCR8-C9orf72 complex. On the 
contrary, depletion of C9orf72 can induce TFEB-mediated autophagy by inhibiting 
mTORC1221, 222. 
Autophagy inducers in ALS 
Autophagy induction has shown beneficial effects in cells harbouring pathogenic SOD1 
mutations. In Neuro2a cells, G93A mutant SOD1 is a substrate for autophagy mediated 
degradation, as pharmacological inhibition of autophagy led to its accumulation whereas 




has reported that p-coumaric acid (active ingredient present in Brazilian green propolis) 
exerted protective effects against neurotoxicity caused by pathogenic SOD1G85R in Neuro2a 
cells via activation of autophagy224.  
Although advantageous effects of enhancing autophagy have been shown for these in vitro 
models, the evidence for in vivo SOD1 models of ALS has been mixed. One study reported 
unexpectedly detrimental effects upon rapamycin treatment in a SOD1G93A mouse model, 
where rapamycin treated mice exhibited earlier onset of disease, shorter lifespan, and greater 
weight loss225. Although the autophagic activity was increased in the motor neurons of these 
mice upon rapamycin treatment, there was no apparent reduction in SOD1 aggregation. The 
observed accelerated disease progression was attributed to activation of the apoptotic 
pathway in spinal cords of ALS mice treated with rapamycin, as confirmed by increased levels 
of cleaved caspase-3225. In contrast, another study in a SOD1G93A mouse model using 
verapamil (L-type channel Ca2+ blocker) showed beneficial effects. Verapamil, an enhancer of 
autophagy, effectively delayed disease onset, prolonged life span, extended disease duration, 
rescued motor neuron survival, reduced SOD1 aggregation, and restored autophagic flux in 
motor neurons226. Furthermore, at least two studies have found beneficial effects of trehalose 
in alleviating ALS disease pathology. In mutant SOD1G86R and SOD1G93A transgenic mice, 
trehalose administration resulted in increased life span, improved neuronal survival, reduced 
astrogliosis and delayed disease onset through activation of autophagy. However, it was 
beneficial only in early stages of the disease and was recommended for use in combination 
with other ALS drugs for asymptomatic patients227,228.  
Other commonly used models of ALS pathology utilise FUS and TDP-43. These are 
aggregrate-prone RNA binding proteins, which are known to cause altered RNA metabolism 
in ALS. Similarly to SOD1, the pathogenic form of TDP-43 is degraded by autophagy229, 230. 
Mutant FUS (mFUS) inhibits autophagy by reducing ATG9 recruitment to autophagosomes 
and concomitantly decreasing autolysosome formation. A study using iPSC-derived neurons 




torkinib and PQR309, expedited the clearance of cytoplasmic FUS and restored altered RNA 
metabolism via autophagy induction231. 
Results from autophagy induction in TDP-43 models have been mixed. Rapamycin was shown 
to be beneficial in a FTLD-TDP transgenic mouse model of ALS232. Autophagy upregulation 
using the novel compounds fluphenazine, methotrimeprazine and 10-(4′-(N-
diethylamino)butyl)-2-chlorophenoxazine in a neuronal model of ALS also reduced TDP-43 
levels and ameliorated pathology233.  However, enhancement of autophagosome biogenesis 
by rapamycin in a Drosophila model of TDP-43 pathology aggravated the disease, whereas 
impeding autophagy by phosphatidic acid (an mTOR agonist234) ameliorated the disease 
phenotype235. 
The complex results obtained from autophagy upregulation in TDP-43 models may be 
explained by the specific defects in autophagy present in the disease. Loss-of TDP-43 function 
may occur in disease conditions when the normally nuclear protein is unable to localise 
correctly. This may have multiple effects on autophagy. TDP-43 stabilizes the mRNA levels of 
RPTOR (a component of mTORC1), and loss of function of TDP-43 results in downregulation 
of RPTOR which affects mTORC1 activity235. TFEB, a positive regulator of autophagosome 
and lysosome biogenesis is phosphorylated by mTORC1, which inhibits its translocation to 
the nucleus. Loss of function of TDP-43 thus causes induction of autophagy by reducing 
mTORC1 activity, consequently enhancing TFEB nuclear translocation. However, this 
autophagy induction is not beneficial as loss of TDP-43 also results in decreased dynactin-1 
levels, which impairs autophagosome-lysosome fusion235. This downstream block in 
autophagic flux may cause a deleterious accumulation of autophagosomes if autophagosome 
formation is induced.  
Genetic approaches in ALS 
In addition to pharmacological studies, several genetic manipulations have been shown to 




substantially for each gene and disease model. For example, genetic ablation of XBP-1 (X-
box-binding protein) in motor neurons of SOD1G86R mice enhanced clearance of mutant SOD1 
aggregates and increased survival through autophagy236. In contrast, conditional knockout of 
ATG7 in motor neurons of SOD1G93A mice led to extended lifespan and reduced cell-
nonautonomous effects on glial cells in the early stages of disease yet accelerated disease 
pathology237.  
Overexpression of Beclin-1 has also yielded complex effects on ALS pathology. BECN1 
overexpression in NSC34 motor neuron cells decreased the aggregation of mutant SOD1G85R 
protein238. In a SOD1G127X mouse model, heterozygous loss of Beclin-1 reduced autophagic 
flux and led to increased SOD1G127X aggregation239. However, haploinsufficiency of BECN1 in 
mutant SOD1G86R transgenic mice was associated with increased life span and reduction in 
mutant SOD1 oligomers, accompanied by an increase in monomeric and high molecular 
weight species impacting aggregation, without an apparent change in mRNA levels238. In this 
case, the reduction in oligomeric species was suggested to be protective. The contrasting 
results between these two studies suggest that different ALS mutations or risk factors may 
interact in different ways with the autophagy pathway. 
Positive results have been obtained in a mFUS model of the disease240. Overexpression of 
Rab1, which mediates intracellular membrane trafficking events, including ER-Golgi trafficking 
and autophagosome formation, rescued autophagosome and autolysosome formation in cells 
expressing mFUS. Moreover, Rab1 overexpression inhibited recruitment of mFUS to stress 
granules (SGs), resulting in a reduction in their size240. 
As ALS is caused by mutations in many different genes which may impact autophagy 
differently, it may be necessary to consider the specific effects of each individual mutation 
when considering autophagy-related therapies. This may be particularly relevant when these 





Conclusion and perspective 
Deficits in protein homeostasis are a shared mechanism across neurodegenerative diseases, 
and therefore increasing protein clearance via autophagy is an attractive strategy that may be 
applicable in multiple diseases. As described above, evidence in disease models indeed 
demonstrates promising results in many cases, with autophagy upregulation being able to 
reduce the levels of toxic proteins, ameliorate signs of disease, and delay disease progression 
in a number of models.  
Effectively utilising autophagy induction as a therapy, however, requires a thorough 
understanding of the interplay between disease pathogenesis and autophagy. Despite the 
strong positive results seen in some models, the complex and often apparently contradictory 
results obtained in other disease models indicate that the effects of autophagy upregulation 
may vary substantially depending on the precise nature of the disease state. The complex and 
varied impairments to autophagy seen in different diseases make it especially important to 
understand how autophagy impacts (and is impacted by) pathogenesis mediated by each 
mutant protein. For instance, as some disease-causing mutations may generate disruptions 
to lysosomal function as part of their pathogenesis, induction of autophagy in these cases may 
result in accumulation of autophagosomes that cannot be degraded, resulting in an 
amplification of the pathological phenotype. The pathophysiology of many neurodegenerative 
diseases is incompletely understood, particularly in sporadic cases of illness.  A better 
understanding of how the autophagy pathway is affected in these cases can help researchers 
to design tailored and effective treatments. It is also important to consider effects autophagy 
may have on pathways unrelated to protein clearance, such as secretion, which may also 
affect disease. 
Upstream signalling pathways such as mTORC1, TFEB and AMPK may exert influence 
across the whole pathway and thus are a potential target to improve flux and overall protein 
clearance. However, while some compounds acting on these pathways (e.g. rapamycin) are 




AMPK may lead to undesirable side effects resulting from their inhibition. As autophagy 
induction may be more beneficial in early stages of disease61, 225, 228, finding modulators with 
mild long-term side effect profiles would be of great therapeutic benefit.  Identifying more 
specific autophagy regulators that are still able to improve flux may lead to drug targets that 
could be modulated in a more clinically tolerable manner. Pharmacokinetic optimisation of 
treatments may also help to reduce side effects from autophagy treatment, and there is some 
evidence that pulsatile treatment may suffice to effectively promote protein clearance3 while 




Figure and table legends: 
Figure 1. Defective autophagy and neurodegenerative disease. A number of risk genes linked 
to neurodegenerative diseases play a role in the autophagy pathway. These genes intersect 
with the autophagy pathway at many different stages, as indicated here. Disruptions to 
autophagy caused by pathogenic changes to the relevant genes may contribute to disease 
pathogenesis. 
Figure 2. Small molecule inducers of autophagy and their mechanisms of action. Autophagy 
is regulated by the mTORC1 pathway and inhibitors of mTORC1, including rapamycin and 
rapalogs, are among the best studied class of autophagy inducers. Other modulators are 
classed as mTOR-independent, and act on various targets including AMPK, IP3 signalling, and 
Ca2+ signalling. 
Table 1. Autophagy inducing molecules that have been tested in models of neurodegenerative 
disease and pilot clinical studies. 
Acknowledgements: 
We are grateful for funding from the UK Dementia Research Institute (funded by the MRC, 
Alzheimer’s Research UK and the Alzheimer’s Society), Roger de Spoelberch Foundation, 
Alzheimer’s Research UK, The Tau Consortium, Cambridge Centre for Parkinson-Plus, 
National Institute for Health Research Cambridge Biomedical Research Centre (D.C.R.), 
Cambridge Commonwealth, European & International Trust (to AD, SK, and RP); Romanian 
grant of Ministry of Research and Innovation CNCS –UEFISCDI, project number PN-III-P1-
1.1-PD-2016-1291, within PNCDI III (to MP); the National Institutes of Health Oxford-
Cambridge Scholars Program (to RP); Cambridge Australia Scholarships (to AD); the Nehru 
Trust for Cambridge University (to SK); the Trinity-Henry Barlow Scholarship (to SK); Udayan 
Care (to SK); the UK Medical Research Council (to LR); and the Raymond and Beverly Sackler 
Fund (to LR). The views expressed are those of the author(s) and not necessarily those of the 








[1] Menzies FM, Fleming A, Caricasole A, Bento CF, Andrews SP, Ashkenazi A, et al. Autophagy and 
Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities. Neuron. 2017;93:1015-
34. 
[2] Bento CF, Renna M, Ghislat G, Puri C, Ashkenazi A, Vicinanza M, et al. Mammalian autophagy: how 
does it work? Annu Rev Biochem. 2016;85:685-713. 
[3] Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al. Inhibition of mTOR induces 
autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington 
disease. Nat Genet. 2004;36:585-95. 
[4] Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-Synuclein is degraded by both 
autophagy and the proteasome. J Biol Chem. 2003;278:25009-13. 
[5] Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy 
reduces neurodegeneration in a mouse model of human tauopathy. Brain. 2012;135:2169-77. 
[6] Winslow AR, Rubinsztein DC. The Parkinson disease protein alpha-synuclein inhibits autophagy. 
Autophagy. 2011;7:429-31. 
[7] Ashkenazi A, Bento CF, Ricketts T, Vicinanza M, Siddiqi F, Pavel M, et al. Polyglutamine tracts 
regulate beclin 1-dependent autophagy. Nature. 2017;545:108-11. 
[8] Menzies FM, Fleming A, Rubinsztein DC. Compromised autophagy and neurodegenerative 
diseases. Nat Rev Neurosci. 2015;16:345-57. 
[9] Rubinsztein DC, Shpilka T, Elazar Z. Mechanisms of autophagosome biogenesis. Curr Biol. 
2012;22:R29-34. 
[10] Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy 
and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672-6. 
[11] Russell RC, Tian Y, Yuan H, Park HW, Chang YY, Kim J, et al. ULK1 induces autophagy by 
phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat Cell Biol. 2013;15:741-50. 
[12] Fujita N, Hayashi-Nishino M, Fukumoto H, Omori H, Yamamoto A, Noda T, et al. An Atg4B mutant 
hampers the lipidation of LC3 paralogues and causes defects in autophagosome closure. Mol Biol Cell. 
2008;19:4651-9. 
[13] Kimura S, Noda T, Yoshimori T. Dynein-dependent movement of autophagosomes mediates 
efficient encounters with lysosomes. Cell Struct Funct. 2008;33:109-22. 
[14] Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, et al. Nutrient-dependent mTORC1 
association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009;20:1981-
91. 
[15] Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, et al. TFEB links 
autophagy to lysosomal biogenesis. Science. 2011;332:1429-33. 
[16] Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162-72. 
[17] Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington's Disease: Mechanisms 
of Pathogenesis and Therapeutic Strategies. Cold Spring Harb Perspect Med. 2017;7:a024240. 
[18] Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, et al. Targeting alpha-synuclein for 
treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 
2015;14:855-66. 
[19] De Strooper B, Karran E. The Cellular Phase of Alzheimer's Disease. Cell. 2016;164:603-15. 
[20] Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 
2001;24:1121-59. 
[21] Hansen M, Rubinsztein DC, Walker DW. Autophagy as a promoter of longevity: insights from 
model organisms. Nat Rev Mol Cell Biol. 2018;19:579-93. 
[22] Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, et al. The autophagy-related 
protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta 
accumulation in mice. J Clin Invest. 2008;118:2190-9. 




[24] Shibata M, Lu T, Furuya T, Degterev A, Mizushima N, Yoshimori T, et al. Regulation of intracellular 
accumulation of mutant Huntingtin by Beclin 1. J Biol Chem. 2006;281:14474-85. 
[25] Rohn TT, Wirawan E, Brown RJ, Harris JR, Masliah E, Vandenabeele P. Depletion of Beclin-1 due 
to proteolytic cleavage by caspases in the Alzheimer's disease brain. Neurobiol Dis. 2011;43:68-78. 
[26] Brehme M, Voisine C, Rolland T, Wachi S, Soper JH, Zhu Y, et al. A chaperome subnetwork 
safeguards proteostasis in aging and neurodegenerative disease. Cell Rep. 2014;9:1135-50. 
[27] Pavel M, Imarisio S, Menzies FM, Jimenez-Sanchez M, Siddiqi FH, Wu X, et al. CCT complex 
restricts neuropathogenic protein aggregation via autophagy. Nat Commun. 2016;7:13821. 
[28] Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, et al. Meta-analysis confirms CR1, CLU, 
and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 
2010;67:1473-84. 
[29] Ando K, Brion JP, Stygelbout V, Suain V, Authelet M, Dedecker R, et al. Clathrin adaptor 
CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer's brains. Acta 
Neuropathol. 2013;125:861-78. 
[30] Moreau K, Fleming A, Imarisio S, Lopez Ramirez A, Mercer JL, Jimenez-Sanchez M, et al. PICALM 
modulates autophagy activity and tau accumulation. Nat Commun. 2014;5:4998. 
[31] Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, et al. Lysosomal proteolysis and 
autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 
2010;141:1146-58. 
[32] Lee JK, Jin HK, Park MH, Kim BR, Lee PH, Nakauchi H, et al. Acid sphingomyelinase modulates the 
autophagic process by controlling lysosomal biogenesis in Alzheimer's disease. J Exp Med. 
2014;211:1551-70. 
[33] Ji ZS, Mullendorff K, Cheng IH, Miranda RD, Huang Y, Mahley RW. Reactivity of apolipoprotein E4 
and amyloid beta peptide: lysosomal stability and neurodegeneration. J Biol Chem. 2006;281:2683-
92. 
[34] Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway 
abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: 
differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157:277-86. 
[35] Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-
mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523-7. 
[36] Xu W, Weissmiller AM, White JA, 2nd, Fang F, Wang X, Wu Y, et al. Amyloid precursor protein-
mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J Clin 
Invest. 2016;126:1815-33. 
[37] Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. Autophagy induction and 
autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J 
Neurosci. 2008;28:6926-37. 
[38] Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive involvement of 
autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 
2005;64:113-22. 
[39] Ejlerskov P, Ashkenazi A, Rubinsztein DC. Genetic enhancement of macroautophagy in vertebrate 
models of neurodegenerative diseases. Neurobiol Dis. 2019;122:3-8. 
[40] Lopez A, Lee SE, Wojta K, Ramos EM, Klein E, Chen J, et al. A152T tau allele causes 
neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. Brain. 
2017;140:1128-46. 
[41] Jiang T, Yu JT, Zhu XC, Zhang QQ, Cao L, Wang HF, et al. Temsirolimus attenuates tauopathy in 
vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. 
Neuropharmacology. 2014;85:121-30. 
[42] Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, Breu K, et al. Rapamycin attenuates the 




[43] Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR 
by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of 
Alzheimer's disease. PLoS One. 2010;5:e9979. 
[44] Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, et al. Rapamycin 
alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006;15:433-42. 
[45] Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent 
autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 
2007;282:5641-52. 
[46] Renna M, Jimenez-Sanchez M, Sarkar S, Rubinsztein DC. Chemical inducers of autophagy that 
enhance the clearance of mutant proteins in neurodegenerative diseases. J Biol Chem. 
2010;285:11061-7. 
[47] DeBosch BJ, Heitmeier MR, Mayer AL, Higgins CB, Crowley JR, Kraft TE, et al. Trehalose inhibits 
solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis. Sci Signal. 
2016;9:ra21. 
[48] Rodriguez-Navarro JA, Rodriguez L, Casarejos MJ, Solano RM, Gomez A, Perucho J, et al. Trehalose 
ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through 
autophagy activation. Neurobiol Dis. 2010;39:423-38. 
[49] Luengo E, Buendia I, Fernandez-Mendivil C, Trigo-Alonso P, Negredo P, Michalska P, et al. 
Pharmacological doses of melatonin impede cognitive decline in tau-related Alzheimer models, once 
tauopathy is initiated, by restoring the autophagic flux. J Pineal Res. 2019;67:e12578. 
[50] Hashimoto Y, Niikura T, Tajima H, Yasukawa T, Sudo H, Ito Y, et al. A rescue factor abolishing 
neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl 
Acad Sci U S A. 2001;98:6336-41. 
[51] Han K, Jia N, Zhong Y, Shang X. S14G-humanin alleviates insulin resistance and increases 
autophagy in neurons of APP/PS1 transgenic mouse. J Cell Biochem. 2018;119:3111-7. 
[52] Ou Z, Kong X, Sun X, He X, Zhang L, Gong Z, et al. Metformin treatment prevents amyloid plaque 
deposition and memory impairment in APP/PS1 mice. Brain Behav Immun. 2018;69:351-63. 
[53] Lonskaya I, Hebron ML, Selby ST, Turner RS, Moussa CE. Nilotinib and bosutinib modulate pre-
plaque alterations of blood immune markers and neuro-inflammation in Alzheimer's disease models. 
Neuroscience. 2015;304:316-27. 
[54] Lonskaya I, Hebron ML, Desforges NM, Schachter JB, Moussa CE. Nilotinib-induced autophagic 
changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med 
(Berl). 2014;92:373-86. 
[55] Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, et al. Metformin in Amnestic 
Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial. J 
Alzheimers Dis. 2016;51:501-14. 
[56] Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the insulin 
sensitizer metformin in Alzheimer’s disease: Pilot data from a randomized placebo-controlled 
crossover study. Alzheimer Dis Assoc Disord. 2017;31:107. 
[57] Son SM, Shin HJ, Byun J, Kook SY, Moon M, Chang YJ, et al. Metformin Facilitates Amyloid-beta 
Generation by beta- and gamma-Secretases via Autophagy Activation. J Alzheimers Dis. 2016;51:1197-
208. 
[58] Kuhla A, Brichmann E, Ruhlmann C, Thiele R, Meuth L, Vollmar B. Metformin Therapy Aggravates 
Neurodegenerative Processes in ApoE-/- Mice. J Alzheimers Dis. 2019;68:1415-27. 
[59] Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, et al. Lithium induces autophagy by 
inhibiting inositol monophosphatase. J Cell Biol. 2005;170:1101-11. 
[60] Cardenas C, Miller RA, Smith I, Bui T, Molgo J, Muller M, et al. Essential regulation of cell 
bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell. 2010;142:270-83. 
[61] Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, et al. Long-term treatment with lithium alleviates 
memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic 




[62] Chong CM, Ke M, Tan Y, Huang Z, Zhang K, Ai N, et al. Presenilin 1 deficiency suppresses autophagy 
in human neural stem cells through reducing gamma-secretase-independent ERK/CREB signaling. Cell 
Death Dis. 2018;9:879. 
[63] Luo R, Su LY, Li G, Yang J, Liu Q, Yang LX, et al. Activation of PPARA-mediated autophagy reduces 
Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy. 2019:1-18. 
[64] Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium 
treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J 
Psychiatry. 2019:1-7. 
[65] Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and 
tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry. 2008;23:704-11. 
[66] Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, et al. Lithium trial in Alzheimer's 
disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 
2009;70:922-31. 
[67] Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, et al. Novel targets for Huntington's 
disease in an mTOR-independent autophagy pathway. Nat Chem Biol. 2008;4:295-305. 
[68] Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. 
Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010;90:1383-
435. 
[69] Underwood BR, Green-Thompson ZW, Pugh PJ, Lazic SE, Mason SL, Griffin J, et al. An open-label 
study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease. 
J Neurol. 2017;264:2457-63. 
[70] Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, et al. Evidence for 
a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's 
diseases. Hum Mol Genet. 2012;21:3500-12. 
[71] Siddiqi FH, Menzies FM, Lopez A, Stamatakou E, Karabiyik C, Ureshino R, et al. Felodipine induces 
autophagy in mouse brains with pharmacokinetics amenable to repurposing. Nat Commun. 
2019;10:1817. 
[72] Medeiros R, Kitazawa M, Chabrier MA, Cheng D, Baglietto-Vargas D, Kling A, et al. Calpain inhibitor 
A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am 
J Pathol. 2012;181:616-25. 
[73] Rocchi A, Yamamoto S, Ting T, Fan Y, Sadleir K, Wang Y, et al. A Becn1 mutation mediates 
hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's 
disease. PLoS Genet. 2017;13:e1006962. 
[74] Khandelwal PJ, Herman AM, Hoe HS, Rebeck GW, Moussa CE. Parkin mediates beclin-dependent 
autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models. Hum Mol 
Genet. 2011;20:2091-102. 
[75] Nilsson P, Loganathan K, Sekiguchi M, Matsuba Y, Hui K, Tsubuki S, et al. Aβ secretion and plaque 
formation depend on autophagy. Cell Rep. 2013;5:61-9. 
[76] Rao MV, McBrayer MK, Campbell J, Kumar A, Hashim A, Sershen H, et al. Specific calpain inhibition 
by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L 
mice. J Neurosci. 2014;34:9222-34. 
[77] Menzies FM, Garcia-Arencibia M, Imarisio S, O'Sullivan NC, Ricketts T, Kent BA, et al. Calpain 
inhibition mediates autophagy-dependent protection against polyglutamine toxicity. Cell Death Differ. 
2015;22:433-44. 
[78] Pavel M, Rubinsztein DC. Autophagy Upregulation as a Therapeutic Strategy for 
Neurodegenerative Diseases. In: Fang FE, Ng BT, editors. Antitumor Potential and other Emerging 
Medicinal Properties of Natural Compounds. Dordrecht: Springer Netherlands; 2013. p. 227-38. 
[79] Polito VA, Li H, Martini-Stoica H, Wang B, Yang L, Xu Y, et al. Selective clearance of aberrant tau 
proteins and rescue of neurotoxicity by transcription factor EB. EMBO Mol Med. 2014;6:1142-60. 
[80] Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy 




[81] Schöndorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, et al. iPSC-derived neurons 
from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium 
homeostasis. Nat Commun. 2014;5:4028. 
[82] Karabiyik C, Lee MJ, Rubinsztein DC. Autophagy impairment in Parkinson's disease. Essays 
Biochem. 2017;61:711-20. 
[83] Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000;404:394-8. 
[84] Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic 
loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative 
disorders. Science. 2000;287:1265-9. 
[85] Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, et al. Genomic 
investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008;63:743-50. 
[86] Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-
synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045-7. 
[87] Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene 
encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106-8. 
[88] Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the 
parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605-8. 
[89] Ii K, Ito H, Tanaka K, Hirano A. Immunocytochemical co-localization of the proteasome in 
ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol. 
1997;56:125-31. 
[90] Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-
mediated autophagy and macroautophagy in neuronal cells. J Biol Chem. 2008;283:23542-56. 
[91] Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, et al. Dopamine-
modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest. 2008;118:777-88. 
[92] Moors T, Paciotti S, Chiasserini D, Calabresi P, Parnetti L, Beccari T, et al. Lysosomal Dysfunction 
and alpha-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links. Mov Disord. 2016;31:791-
801. 
[93] Yu WH, Dorado B, Figueroa HY, Wang L, Planel E, Cookson MR, et al. Metabolic activity determines 
efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol. 
2009;175:736-47. 
[94] Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant 
alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292-5. 
[95] Tenreiro S, Reimao-Pinto MM, Antas P, Rino J, Wawrzycka D, Macedo D, et al. Phosphorylation 
modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet. 
2014;10:e1004302. 
[96] Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA, et al. alpha-
Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol. 2010;190:1023-
37. 
[97] Zavodszky E, Seaman MN, Moreau K, Jimenez-Sanchez M, Breusegem SY, Harbour ME, et al. 
Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits 
autophagy. Nat Commun. 2014;5:3828. 
[98] Tang FL, Erion JR, Tian Y, Liu W, Yin DM, Ye J, et al. VPS35 in Dopamine Neurons Is Required for 
Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is 
Critical for alpha-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease. J 
Neurosci. 2015;35:10613-28. 
[99] Lonskaya I, Hebron ML, Algarzae NK, Desforges N, Moussa CE. Decreased parkin solubility is 
associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease. 
Neuroscience. 2013;232:90-105. 
[100] Tanik SA, Schultheiss CE, Volpicelli-Daley LA, Brunden KR, Lee VM. Lewy body-like alpha-





[101] Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 
1996;47:S161-70. 
[102] Chen L, Xie Z, Turkson S, Zhuang X. A53T human alpha-synuclein overexpression in transgenic 
mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron 
degeneration. J Neurosci. 2015;35:890-905. 
[103] Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, et al. The risk of Parkinson's disease 
in type 1 Gaucher disease. J Inherit Metab Dis. 2010;33:167-73. 
[104] Bento CF, Ashkenazi A, Jimenez-Sanchez M, Rubinsztein DC. The Parkinson's disease-associated 
genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat Commun. 2016;7:11803. 
[105] Bove J, Martinez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic 
insights. Nat Rev Neurosci. 2011;12:437-52. 
[106] Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, et al. Pathogenic lysosomal 
depletion in Parkinson's disease. J Neurosci. 2010;30:12535-44. 
[107] Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, et al. Selective molecular 
alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-
synucleinopathy. PLoS One. 2010;5:e9313. 
[108] Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against 
neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci. 2010;30:1166-75. 
[109] Bai X, Wey MC, Fernandez E, Hart MJ, Gelfond J, Bokov AF, et al. Rapamycin improves motor 
function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a 
mouse model of synucleinopathy. Pathobiol Aging Age Relat Dis. 2015;5:28743. 
[110] Kim YC, Guan KL. MTOR: A pharmacologic target for autophagy regulation.  J Clin Invest2015. 
[111] Renna M, Bento CF, Fleming A, Menzies FM, Siddiqi FH, Ravikumar B, et al. IGF-1 receptor 
antagonism inhibits autophagy. Hum Mol Genet. 2013;22:4528-44. 
[112] Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, et al. Small molecules 
enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol. 2007;3:331-
8. 
[113] Sarkar S, Rubinsztein DC. Small molecule enhancers of autophagy for neurodegenerative 
diseases. Mol Biosyst. 2008;4:895-901. 
[114] Sarkar S, Chigurupati S, Raymick J, Mann D, Bowyer JF, Schmitt T, et al. Neuroprotective effect 
of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model. 
Neurotoxicology. 2014;44:250-62. 
[115] He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, et al. Treatment with Trehalose Prevents 
Behavioral and Neurochemical Deficits Produced in an AAV alpha-Synuclein Rat Model of Parkinson's 
Disease. Mol Neurobiol. 2016;53:2258-68. 
[116] Palmieri M, Pal R, Nelvagal HR, Lotfi P, Stinnett GR, Seymour ML, et al. mTORC1-independent 
TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. 
Nat Commun. 2017;8:14338. 
[117] Pupyshev AB, Tikhonova MA, Akopyan AA, Tenditnik MV, Dubrovina NI, Korolenko TA. 
Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse 
MPTP-induced model of Parkinson's disease. Pharmacol Biochem Behav. 2019;177:1-11. 
[118] Dulovic M, Jovanovic M, Xilouri M, Stefanis L, Harhaji-Trajkovic L, Kravic-Stevovic T, et al. The 
protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiol 
Dis. 2014;63:1-11. 
[119] Ng CH, Guan MS, Koh C, Ouyang X, Yu F, Tan EK, et al. AMP kinase activation mitigates 
dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's 
disease. J Neurosci. 2012;32:14311-7. 
[120] Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S. Neuroprotective effect of metformin in 
MPTP-induced Parkinson's disease in mice. Neuroscience. 2014;277:747-54. 
[121] Yu HC, Lin CS, Tai WT, Liu CY, Shiau CW, Chen KF. Nilotinib induces autophagy in hepatocellular 




[122] Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves 
motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum 
Mol Genet. 2013;22:3315-28. 
[123] Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS. The c-Abl inhibitor, 
nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Sci Rep. 
2014;4:4874. 
[124] Simuni T, Fiske B, Merchant K, Coffey C, Matthews H, Wyse RK, et al. NILO-PD: A Phase 2A Study 
of Nilotinib in Patients with Advanced and Early Parkinson’s Disease: Study Design and Status Update 
(P3. 8-035). AAN Enterprises; 2019. 
[125] Ferretta A, Gaballo A, Tanzarella P, Piccoli C, Capitanio N, Nico B, et al. Effect of resveratrol on 
mitochondrial function: implications in parkin-associated familiar Parkinson's disease. Biochim 
Biophys Acta. 2014;1842:902-15. 
[126] Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, et al. Resveratrol ameliorates aging-related 
metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148:421-33. 
[127] Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, et al. Resveratrol-activated AMPK/SIRT1/autophagy in 
cellular models of Parkinson's disease. Neurosignals. 2011;19:163-74. 
[128] Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, Khuwaja G, et al. Resveratrol attenuates 6-
hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's 
disease. Brain Res. 2010;1328:139-51. 
[129] Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced 
Parkinson's disease in rats. Eur J Pharmacol. 2008;600:78-82. 
[130] Blanchet J, Longpre F, Bureau G, Morissette M, DiPaolo T, Bronchti G, et al. Resveratrol, a red 
wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol 
Biol Psychiatry. 2008;32:1243-50. 
[131] Lu JH, Tan JQ, Durairajan SS, Liu LF, Zhang ZH, Ma L, et al. Isorhynchophylline, a natural alkaloid, 
promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy. 
2012;8:98-108. 
[132] Wang K, Huang J, Xie W, Huang L, Zhong C, Chen Z. Beclin1 and HMGB1 ameliorate the alpha-
synuclein-mediated autophagy inhibition in PC12 cells. Diagn Pathol. 2016;11:15. 
[133] Song JX, Lu JH, Liu LF, Chen LL, Durairajan SS, Yue Z, et al. HMGB1 is involved in autophagy 
inhibition caused by SNCA/alpha-synuclein overexpression: a process modulated by the natural 
autophagy inducer corynoxine B. Autophagy. 2014;10:144-54. 
[134] Chen LL, Song JX, Lu JH, Yuan ZW, Liu LF, Durairajan SS, et al. Corynoxine, a natural autophagy 
enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway. J Neuroimmune 
Pharmacol. 2014;9:380-7. 
[135] Hou L, Xiong N, Liu L, Huang J, Han C, Zhang G, et al. Lithium protects dopaminergic cells from 
rotenone toxicity via autophagy enhancement. BMC Neurosci. 2015;16:82. 
[136] Lieu CA, Dewey CM, Chinta SJ, Rane A, Rajagopalan S, Batir S, et al. Lithium prevents parkinsonian 
behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model. Brain Res. 
2014;1591:111-7. 
[137] Duka T, Duka V, Joyce JN, Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau 
phosphorylation in Parkinson's disease models. FASEB J. 2009;23:2820-30. 
[138] Xiong N, Jia M, Chen C, Xiong J, Zhang Z, Huang J, et al. Potential autophagy enhancers attenuate 
rotenone-induced toxicity in SH-SY5Y. Neuroscience. 2011;199:292-302. 
[139] Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. Rapamycin and mTOR-independent autophagy 
inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell 
Death Differ. 2009;16:46-56. 
[140] Li XZ, Chen XP, Zhao K, Bai LM, Zhang H, Zhou XP. Therapeutic effects of valproate combined 
with lithium carbonate on MPTP-induced parkinsonism in mice: possible mediation through enhanced 




[141] Martini-Stoica H, Xu Y, Ballabio A, Zheng H. The Autophagy-Lysosomal Pathway in 
Neurodegeneration: A TFEB Perspective. Trends Neurosci. 2016;39:221-34. 
[142] Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjorklund A. TFEB-mediated 
autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc Natl Acad Sci U S 
A. 2013;110:E1817-26. 
[143] Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, et al. Beclin 1 gene transfer 
activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of 
Parkinson's and Lewy body diseases. J Neurosci. 2009;29:13578-88. 
[144] Fan HC, Ho LI, Chi CS, Chen SJ, Peng GS, Chan TM, et al. Polyglutamine (PolyQ) diseases: genetics 
to treatments. Cell Transplant. 2014;23:441-58. 
[145] Martinez-Vicente M, Talloczy Z, Wong E, Tang GM, Koga H, Kaushik S, et al. Cargo recognition 
failure is responsible for inefficient autophagy in Huntington's disease. Nature Neuroscience. 
2010;13:567-U74. 
[146] Rui YN, Xu Z, Patel B, Chen ZH, Chen DS, Tito A, et al. Huntingtin functions as a scaffold for 
selective macroautophagy. Nature Cell Biology. 2015;17:262-+. 
[147] Ochaba J, Lukacsovich T, Csikos G, Zheng SQ, Margulis J, Salazar L, et al. Potential function for 
the Huntingtin protein as a scaffold for selective autophagy. Proc Natl Acad Sci U S A. 2014;111:16889-
94. 
[148] Zheng S, Clabough EB, Sarkar S, Futter M, Rubinsztein DC, Zeitlin SO. Deletion of the huntingtin 
polyglutamine stretch enhances neuronal autophagy and longevity in mice. PLoS Genet. 
2010;6:e1000838. 
[149] Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky-Gold B, et al. Disruption 
of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. 
Neuron. 2003;40:25-40. 
[150] Maday S, Wallace KE, Holzbaur EL. Autophagosomes initiate distally and mature during transport 
toward the cell soma in primary neurons. J Cell Biol. 2012;196:407-17. 
[151] Ravikumar B, Acevedo-Arozena A, Imarisio S, Berger Z, Vacher C, O'Kane CJ, et al. Dynein 
mutations impair autophagic clearance of aggregate-prone proteins. Nat Genet. 2005;37:771-6. 
[152] Szebenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, Stenoien DL, et al. Neuropathogenic 
forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron. 2003;40:41-52. 
[153] Wong YC, Holzbaur ELF. The Regulation of Autophagosome Dynamics by Huntingtin and HAP1 Is 
Disrupted by Expression of Mutant Huntingtin, Leading to Defective Cargo Degradation. Journal of 
Neuroscience. 2014;34:1293-305. 
[154] Caviston JP, Ross JL, Antony SM, Tokito M, Holzbaur EL. Huntingtin facilitates dynein/dynactin-
mediated vesicle transport. Proc Natl Acad Sci U S A. 2007;104:10045-50. 
[155] Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell 
Death Differ. 2011;18:571-80. 
[156] Cortes CJ, Miranda HC, Frankowski H, Batlevi Y, Young JE, Le A, et al. Polyglutamine-expanded 
androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. Nat Neurosci. 
2014;17:1180-9. 
[157] Napolitano G, Ballabio A. TFEB at a glance. J Cell Sci. 2016;129:2475-81. 
[158] Baron O, Boudi A, Dias C, Schilling M, Nolle A, Vizcay-Barrena G, et al. Stall in Canonical 
Autophagy-Lysosome Pathways Prompts Nucleophagy-Based Nuclear Breakdown in 
Neurodegeneration. Curr Biol. 2017;27:3626-42 e6. 
[159] Nisoli I, Chauvin J, Napoletano F, Calamita P, Zanin V, Fanto M, et al. Neurodegeneration by 
polyglutamine Atrophin is not rescued by induction of autophagy. Cell Death Differ. 2010;17:1577. 
[160] Shao J, Diamond MI. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. 
Hum Mol Genet. 2007;16 Spec No. 2:R115-23. 
[161] Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and 




[162] Verhoef LG, Lindsten K, Masucci MG, Dantuma NP. Aggregate formation inhibits proteasomal 
degradation of polyglutamine proteins. Hum Mol Genet. 2002;11:2689-700. 
[163] Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, et al. Trehalose alleviates polyglutamine-
mediated pathology in a mouse model of Huntington disease. Nat Med. 2004;10:148-54. 
[164] Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC. A rational mechanism for 
combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet. 
2007;17:170-8. 
[165] Fleming A, Noda T, Yoshimori T, Rubinsztein DC. Chemical modulators of autophagy as biological 
probes and potential therapeutics. Nat Chem Biol. 2011;7:9-17. 
[166] Sarkar S, Korolchuk VI, Renna M, Imarisio S, Fleming A, Williams A, et al. Complex inhibitory 
effects of nitric oxide on autophagy. Mol Cell. 2011;43:19-32. 
[167] Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner S. A small-molecule scaffold 
induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. 
Proc Natl Acad Sci U S A. 2010;107:16982-7. 
[168] Abd-Elrahman KS, Hamilton A, Hutchinson SR, Liu F, Russell RC, Ferguson SSG. mGluR5 
antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of 
Huntington's disease. Sci Signal. 2017;10:eaan6387. 
[169] Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, et al. Testosterone reduction prevents 
phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 
2002;35:843-54. 
[170] Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, et al. Androgen-dependent 
neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 
2002;35:855-64. 
[171] Iwata A, Christianson JC, Bucci M, Ellerby LM, Nukina N, Forno LS, et al. Increased susceptibility 
of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Natl Acad Sci 
U S A. 2005;102:13135-40. 
[172] Baniahmad A. Inhibition of the Androgen Receptor by Antiandrogens in Spinobulbar Muscle 
Atrophy. J Mol Neurosci. 2016;58:343-7. 
[173] Rusmini P, Bolzoni E, Crippa V, Onesto E, Sau D, Galbiati M, et al. Proteasomal and autophagic 
degradative activities in spinal and bulbar muscular atrophy. Neurobiol Dis. 2010;40:361-9. 
[174] Giorgetti E, Rusmini P, Crippa V, Cristofani R, Boncoraglio A, Cicardi ME, et al. Synergic 
prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible 
for spinal and bulbar muscular atrophy. Hum Mol Genet. 2015;24:64-75. 
[175] Walter C, Clemens LE, Muller AJ, Fallier-Becker P, Proikas-Cezanne T, Riess O, et al. Activation of 
AMPK-induced autophagy ameliorates Huntington disease pathology in vitro. Neuropharmacology. 
2016;108:24-38. 
[176] Ravikumar B, Imarisio S, Sarkar S, O'Kane CJ, Rubinsztein DC. Rab5 modulates aggregation and 
toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease. J 
Cell Sci. 2008;121:1649-60. 
[177] Vidal RL, Figueroa A, Court FA, Thielen P, Molina C, Wirth C, et al. Targeting the UPR transcription 
factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy. 
Hum Mol Genet. 2012;21:2245-62. 
[178] Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, Roque RA, et al. PGC-1alpha rescues 
Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci 
Transl Med. 2012;4:142ra97. 
[179] Aron R, Pellegrini P, Green EW, Maddison DC, Opoku-Nsiah K, Wong JS, et al. Deubiquitinase 
Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of 
Huntington’s disease. Nat Commun. 2018;9:3191. 
[180] Khalil B, El Fissi N, Aouane A, Cabirol-Pol MJ, Rival T, Lievens JC. PINK1-induced mitophagy 




[181] Nascimento-Ferreira I, Santos-Ferreira T, Sousa-Ferreira L, Auregan G, Onofre I, Alves S, et al. 
Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-
Joseph disease. Brain. 2011;134:1400-15. 
[182] Nascimento-Ferreira I, Nobrega C, Vasconcelos-Ferreira A, Onofre I, Albuquerque D, Aveleira C, 
et al. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-
Joseph disease. Brain. 2013;136:2173-88. 
[183] Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, et al. Controversies and 
priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310-22. 
[184] Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn 
superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 
1993;362:59. 
[185] Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, 
an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 
2009;323:1208-11. 
[186] Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial 
and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668-72. 
[187] Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al. SQSTM1 mutations in familial and sporadic 
amyotrophic lateral sclerosis. Arch Neurol. 2011;68:1440-6. 
[188] Teyssou E, Takeda T, Lebon V, Boillee S, Doukoure B, Bataillon G, et al. Mutations in SQSTM1 
encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. Acta Neuropathol. 
2013;125:511-22. 
[189] Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in 
amyotrophic lateral sclerosis. Nature. 2010;465:223-6. 
[190] Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome 
Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron. 2010;68:857-64. 
[191] Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Muller K, et al. Haploinsufficiency of 
TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18:631-6. 
[192] Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 
cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477:211-5. 
[193] Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, et al. Mutant dynactin in motor 
neuron disease. Nat Genet. 2003;33:455-6. 
[194] Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, et al. A gene encoding a 
putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet. 
2001;29:166. 
[195] Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, et al. Mutations in the profilin 1 
gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499-503. 
[196] Parkinson N, Ince PG, Smith MO, Highley R, Skibinski G, Andersen PM, et al. ALS phenotypes with 
mutations in CHMP2B (charged multivesicular body protein 2B). Neurology. 2006;67:1074-7. 
[197] Cox LE, Ferraiuolo L, Goodall EF, Heath PR, Higginbottom A, Mortiboys H, et al. Mutations in 
CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). PLoS One. 
2010;5:e9872. 
[198] Chow CY, Landers JE, Bergren SK, Sapp PC, Grant AE, Jones JM, et al. Deleterious variants of FIG4, 
a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet. 2009;84:85-8. 
[199] DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. 
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-
linked FTD and ALS. Neuron. 2011;72:245-56. 
[200] Taylor JP, Brown RH, Jr., Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 
2016;539:197-206. 
[201] Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, et al. Aggregation and 





[202] Scotter EL, Chen H-J, Shaw CE. TDP-43 proteinopathy and ALS: insights into disease mechanisms 
and therapeutic targets. Neurotherapeutics. 2015;12:352-63. 
[203] Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, et al. TARDBP mutations in 
amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. 
Lancet Neurol. 2008;7:409-16. 
[204] Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. 
Autophagy. 2011;7:279-96. 
[205] Zaffagnini G, Martens S. Mechanisms of Selective Autophagy. J Mol Biol. 2016;428:1714-24. 
[206] Goode A, Butler K, Long J, Cavey J, Scott D, Shaw B, et al. Defective recognition of LC3B by mutant 
SQSTM1/p62 implicates impairment of autophagy as a pathogenic mechanism in ALS-FTLD. 
Autophagy. 2016;12:1094-104. 
[207] Fifita JA, Williams KL, Sundaramoorthy V, McCann EP, Nicholson GA, Atkin JD, et al. A novel 
amyotrophic lateral sclerosis mutation in OPTN induces ER stress and Golgi fragmentation in vitro. 
Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:126-33. 
[208] Korac J, Schaeffer V, Kovacevic I, Clement AM, Jungblut B, Behl C, et al. Ubiquitin-independent 
function of optineurin in autophagic clearance of protein aggregates. J Cell Sci. 2013;126:580-92. 
[209] Shen WC, Li HY, Chen GC, Chern Y, Tu PH. Mutations in the ubiquitin-binding domain of 
OPTN/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a 
dominant-negative mechanism. Autophagy. 2015;11:685-700. 
[210] Sundaramoorthy V, Walker AK, Tan V, Fifita JA, Mccann EP, Williams KL, et al. Defects in 
optineurin- and myosin VI-mediated cellular trafficking in amyotrophic lateral sclerosis. Hum Mol 
Genet. 2015;24:3830-46. 
[211] Wu Q, Liu M, Huang C, Liu X, Huang B, Li N, et al. Pathogenic Ubqln2 gains toxic properties to 
induce neuron death. Acta Neuropathol. 2015;129:417-28. 
[212] Topp JD, Gray NW, Gerard RD, Horazdovsky BF. Alsin is a Rab5 and Rac1 guanine nucleotide 
exchange factor. J Biol Chem. 2004;279:24612-23. 
[213] Hadano S, Otomo A, Kunita R, Suzuki-Utsunomiya K, Akatsuka A, Koike M, et al. Loss of 
ALS2/Alsin exacerbates motor dysfunction in a SOD1H46R-expressing mouse ALS model by disturbing 
endolysosomal trafficking. PloS One. 2010;5:e9805. 
[214] Hadano S, Mitsui S, Pan L, Otomo A, Kubo M, Sato K, et al. Functional links between SQSTM1 
and ALS2 in the pathogenesis of ALS: cumulative impact on the protection against mutant SOD1-
mediated motor dysfunction in mice. Hum Mol Genet. 2016;25:3321-40. 
[215] Morimoto N, Nagai M, Ohta Y, Miyazaki K, Kurata T, Morimoto M, et al. Increased autophagy in 
transgenic mice with a G93A mutant SOD1 gene. Brain Res. 2007;1167:112-7. 
[216] Xie Y, Zhou B, Lin MY, Wang S, Foust KD, Sheng ZH. Endolysosomal Deficits Augment 
Mitochondria Pathology in Spinal Motor Neurons of Asymptomatic fALS Mice. Neuron. 2015;87:355-
70. 
[217] Bose JK, Huang CC, Shen CK. Regulation of autophagy by neuropathological protein TDP-43. J 
Biol Chem. 2011;286:44441-8. 
[218] Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu YF, et al. C9ORF72 poly(GA) 
aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci. 
2016;19:668-77. 
[219] Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, et al. The C9orf72 GGGGCC 
Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS. Science. 
2013;339:1335-8. 
[220] Yamakawa M, Ito D, Honda T, Kubo K, Noda M, Nakajima K, et al. Characterization of the 
dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS. Hum Mol Genet. 2015;24:1630-
45. 
[221] Ugolino J, Ji YJ, Conchina K, Chu J, Nirujogi RS, Pandey A, et al. Loss of C9orf72 Enhances 




[222] Nassif M, Woehlbier U, Manque PA. The Enigmatic Role of C9ORF72 in Autophagy. Front 
Neurosci. 2017;11:442. 
[223] Kabuta T, Suzuki Y, Wada K. Degradation of amyotrophic lateral sclerosis-linked mutant Cu,Zn-
superoxide dismutase proteins by macroautophagy and the proteasome. J Biol Chem. 
2006;281:30524-33. 
[224] Ueda T, Ito T, Kurita H, Inden M, Hozumi I. p-Coumaric Acid Has Protective Effects against Mutant 
Copper-Zinc Superoxide Dismutase 1 via the Activation of Autophagy in N2a Cells. Int J Mol Sci. 
2019;20:2942. 
[225] Zhang X, Li L, Chen S, Yang D, Wang Y, Zhang X, et al. Rapamycin treatment augments motor 
neuron degeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. Autophagy. 
2011;7:412-25. 
[226] Zhang X, Chen S, Lu K, Wang F, Deng J, Xu Z, et al. Verapamil Ameliorates Motor Neuron 
Degeneration and Improves Lifespan in the SOD1 G93A Mouse Model of ALS by Enhancing Autophagic 
Flux. Aging Dis. 2019:0. 
[227] Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, et al. Trehalose delays the 
progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy. 
2013;9:1308-20. 
[228] Li Y, Guo Y, Wang X, Yu X, Duan W, Hong K, et al. Trehalose decreases mutant SOD1 expression 
and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-
G93A mouse model. Neuroscience. 2015;298:12-25. 
[229] Wang X, Fan H, Ying Z, Li B, Wang H, Wang G. Degradation of TDP-43 and its pathogenic form by 
autophagy and the ubiquitin-proteasome system. Neurosci Lett. 2010;469:112-6. 
[230] Wang IF, Tsai KJ, Shen CK. Autophagy activation ameliorates neuronal pathogenesis of FTLD-U 
mice: a new light for treatment of TARDBP/TDP-43 proteinopathies. Autophagy. 2013;9:239-40. 
[231] Marrone L, Drexler HCA, Wang J, Tripathi P, Distler T, Heisterkamp P, et al. FUS pathology in ALS 
is linked to alterations in multiple ALS-associated proteins and rescued by drugs stimulating 
autophagy. Acta Neuropathol. 2019;138:67-84. 
[232] Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, et al. Autophagy activators rescue and alleviate 
pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl 
Acad Sci U S A. 2012;109:15024-9. 
[233] Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, Ando DM, et al. Autophagy induction enhances 
TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014;10:677-85. 
[234] Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic 
activation of mTOR signaling. Science. 2001;294:1942-5. 
[235] Xia Q, Wang H, Hao Z, Fu C, Hu Q, Gao F, et al. TDP-43 loss of function increases TFEB activity 
and blocks autophagosome-lysosome fusion. EMBO J. 2016;35:121-42. 
[236] Hetz C, Thielen P, Matus S, Nassif M, Court F, Kiffin R, et al. XBP-1 deficiency in the nervous 
system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 
2009;23:2294-306. 
[237] Rudnick ND, Griffey CJ, Guarnieri P, Gerbino V, Wang X, Piersaint JA, et al. Distinct roles for motor 
neuron autophagy early and late in the SOD1(G93A) mouse model of ALS. Proc Natl Acad Sci U S A. 
2017;114:E8294-E303. 
[238] Nassif M, Valenzuela V, Rojas-Rivera D, Vidal R, Matus S, Castillo K, et al. Pathogenic role of 
BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis. Autophagy. 2014;10:1256-71. 
[239] Tokuda E, Brannstrom T, Andersen PM, Marklund SL. Low autophagy capacity implicated in 
motor system vulnerability to mutant superoxide dismutase. Acta Neuropathol Commun. 2016;4:6. 
[240] Soo KY, Sultana J, King AE, Atkinson RAK, Warraich ST, Sundaramoorthy V, et al. ALS-associated 




Molecule(s) Mechanism of action Disease model 
Rapamycin (and 
rapalogs) 
mTOR inhibition AD: P301S tau transgenic mice (↑tau clearance, improved symptoms)41, 42, PDAPP mice 
(↓Aβ levels, ↑cognitive function)43, R406W tau Drosophila (↓tau levels, ↑survival)44,  
PD: PC12 cells (↓mutant α-syn levels)4, dopaminergic neurons (↓neuronal toxicity)106, 
transgenic α-syn mice (↓α-syn levels)107, MPTP-induced WT mice (↓neuron death)108, A53T 
α-syn mice (↑motor function)109 
HD: mHTT Drosophila (reduced neurodegeneration)3, 164, mHTT mice (↓mHTT aggregates, 
improved behaviour)3 
ALS: SOD1G93A N2a cells (↓mSOD1 levels)223,  FTLD-TDP transgenic mice (↓neuron loss, 
↑learning, memory and motor function)232,  SOD1G93A mice (↓lifespan, accelerated disease 
progression)225 
Trehalose AMPK stimulation AD:  P301S tau transgenic mice (↑tau clearance, ↑neuronal survival)5, PK−/−/TauVLW mice 
(↓tau levels, ↑motor behaviour)48 
PD: PC12 cells (↓mutant α-syn levels)45, MPTP-induced WT mice  (↓dopamine transporter 
loss, ↓neuroinflammation)114, transgenic α-syn rats (prevents deficits in motor 
asymmetry)115 
HD: transgenic mHTT mice (↑motor function, ↑lifespan)163 
ALS: mutant SOD1G86R and SOD1G93A transgenic mice (↑lifespan, ↑neuronal survival)227, 228 
Verapamil L-type channel Ca2+ blocker, 
AMPK activation 
AD: A152T tau zebrafish (↓insoluble tau levels, improved morphological phenotype)71 
HD:  mHTT cells and zebrafish (↓mHTT aggregates, ↓photoreceptor degeneration)67 
ALS: SOD1G93A mice (↓motor neuron degeneration, ↑lifespan)226 
Felodipine L-type Ca2+ channel 
antagonists, AMPK 
activation 
AD: Tau zebrafish (↓insoluble tau levels, improved morphological phenotype)71 
PD: A53T α-syn mice (↓α-syn levels, ↑grip strength)71 
HD: N171-82Q (B6HD) mice (↑motor performance)71 
Lithium GSK3β inhibition, AMPK 
stimulation, IP3 signalling 
AD: APP/PS1 mice (↓Aβ levels, ↑memory)61, pilot clinical trials (mixed; reduced cognitive 
decline in one trial)64-66 
PD:  PC12 cells (↑α-syn clearance)59, SH-SY5Y cells (↓rotenone toxicity)135, Parkin mutant 
mice (↓Parkinsonian phenotypes)136 
SMER10, 18, 28 unknown PD: A53T α-syn cells (↑mutant α-syn clearance)112 
HD: mHTT cells and Drosophila (↓mHTT toxicity)112 
Metformin AMPK stimulation AD: APP/PS1 mice (↓amyloid plaque deposition, ↑memory)52, pilot clinical trials (↑memory, 
↑executive function)55 
PD: SH-SY5Y cells (↓mutant α-syn levels)118, mutant LRRK2 and Parkin-null Drosophila 
(reduced mitochondrial pathology)119, MPTP-induced WT mice (↑motor function)120 
Nilotinib AMPK stimulation AD: TgAPP mice (↑amyloid clearance, ↓inflammatory markers)53, 54 
PD: A53T and WT α-syn overexpression mice (↑dopaminergic neuron survival, -up motor 
function)122, pilot clinical trials (↑cognitive and motor skills)124 
Clonidine and 
rilmenidine 
Imidazoline receptor agonist AD: A152T tau zebrafish (↑tau clearance, improved morphological phenotype)40  
HD:  mHTT cells and zebrafish (↓mHTT aggregates, ↓photoreceptor degeneration)67 
Calpastatin, calpeptin, 
A-705253 
Calpain inhibition AD: 3xTg-AD mice (↑clearance of Aβ and tau, ↑cognitive function)72 





AD: APP/PS1 mice (↑autophagic flux, delayed disease development)32 
Bosutinib AMPK stimulation AD: TgAPP mice (↑amyloid clearance, ↓inflammatory markers)53, 54 
Melatonin AMPK stimulation AD: AAV-hTauP301L mice (↑autophagic flux, ↑memory)49 
Humanin AMPK stimulation AD: APP/PS1 mice (↓Aβ deposition)51 
SB216763 GSK3β inhibition AD: PS1 KO & mutant neurons (↑lysosomal function)62 
Gemfibrozil and 
Wy14643 
PPAR agonist AD: APP/PS1 mice (↑Aβ clearance, ↑cognitive function)63 
Resveratrol AMPK stimulation PD: SH-SY5Y and PC12 cells (↑α-syn clearance)125, 126, 6-OHDA-induced WT rats 
(↓oxidative damage)128, 129, MPTP-induced WT mice (↓neuroinflammation)130 
Corynoxine B mTOR-independent PD: dopaminergic neurons and N2a cells (↑α-syn clearance)131 
Sodium valproate IP3 signalling PD: SH-SY5Y cells (protection against rotenone toxicity)
138, MPTP-induced WT mice 
(↑motor function)140 
Carbamazepine IP3 signalling PD: SH-SY5Y cells (protection against rotenone toxicity)
138 
Minoxidil K+ATP channel activation HD: mHTT cells (↑mHTT clearance)67 
Loperamide Opioid receptor agonist HD: mHTT cells (↑mHTT clearance)67 
p-coumaric acid unknown ALS: SOD1G85R N2a cells (↓mSOD1 levels, ↓oxidative stress)224 
Torkinib and PQR309 mTOR inhibition ALS: FUS expressing iPSC-derived neurons (↑FUS clearance)231, mutant FUS Drosophila 
(improved motor function)231 
Signalling and activation
(mTORC1, TFEB, AMPK, ULK1)
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